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15-Deoxyspergualin (15-DS) is a new immuno-
suppressive agent which showed promising results 
after experimental allogeneic heart, liver, kidney and 
pancreas islet cell transplantation in rodents. 
After renal and hepatic transplantation in rats, 
long-term graft tolerance has been achieved by using 
15-DS; however, very little is so Jar known about the 
efficacy of 15-DS in larger animals. 
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In order to assess the immunosuppressive potentials 
of 15-DS in a preclinical experiment, heterotopic 
cardiac ( n=27, group I) and classical renal ( n=25, 
group II) allotransplantations were performed in 
Chacma baboons. The following immunosuppressive 
regimens were used: 
Groups IA and !IA served as control groups and 
received no medication. 
Groups IE and JIB were treated with 15-DS alone ( 4 
mg/kg/ day) for postoperative days 0-9. 
Groups IC and !IC were treated with Cyclosporine A 
(CyA, 10-40 mg/kg/day) for postoperative days 0-30. 
Groups ID and !ID received the combination of 15-DS 
(for postoperative days 0-9) and CyA (postoperative 
days 0-30). 
Acute rejection episodes were diagnosed using 
cyto-immunological monitoring and weekly 
myocardial or renal core biopsies. 
After cardiac transplantation, the mean graft 
survival was 11. 0 days for group IA, 28.2 days for 
group IE (p <0.05; IE vs. IA), 32.4 days for group IC 
and 43.1 days for group ID (p <0.025; ID vs. IA). 
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After renal transplantation, the corresponding 
figures were 12.3 days for group !IA, 8.5 days for 
group JIB, 30.4 days for group !IC and 148.9 days for 
group ID (p < 0.025; !ID vs. !IA). 
After cardiac and renal transplantation, acute 
rejection was the main cause of graft J ailure. 
Treatment related side effects, mainly gastrointestinal 
complications, were observed only in primates which 
were treated with 15-DS alone, but not when 15-DS 
was combined with CyA. No major infections occurred. 
After cardiac transplantation, permanent graft 
nonreactivity was not achieved, but a delayed 
rejection occurred within a mean of 21.8. days after 
immunosuppression had been stopped. 
Following renal transplantation, graft 
nonreactivity was observed in group !ID after initial 
treatment with 15-DS and CyA. In this group, 4 out of 
8 animals (50%) were graft tolerant up to 340, 256, 
244 and 164 days after treatment discontinuation. 
Thus, the combination of 15-DS and CyA led to a 
significant prolongation of graft survival in both 
groups. Using the same drug combination, long-term 
graft nonreactivity was achieved in a primate model 
after renal transplantation. 
In a second study protocol, the efficacy of 15-DS in 
combination with CyA was tested after heterotopic 
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cardiac xenotransplantation and compared with other 
immunosuppressive protocols. 
Heterotopic heart transplantations were performed 
in the neck using Veruet monkeys as donors and 
Chacma baboons as recipients. The following groups 
were investigated: 
Group I ( n=B): Control, no immunosuppressive 
medication. 
Group II ( n= 5): CyA in combination with 
azathioprine and methylprednisolone. 
Group III ( n=6): CyA, azathioprine and 
methylprednisolone in combination with 
antithymocyte globulin (RATG) for postoperative days 
0-9. 
Group IV ( n= 7): CyA, azathioprine and 
methylprednisolone were combined with 15-DS for 
postoperative days 0-9. 
Due to severe treatment related side effects which 
were observed in group Iv: further immunosuppression 
was modified as follows: 
Group V ( n= 5): 15-DS was combined with CyA 
and methylprednisolone only. 
Acute rejections were treated with 500 mg 
methylprednisolone i.v. as a bolus dose for 3 to 5 
consecutive days. 
The graft survival after xenogeneic heart 
transplantation was best in group III with 43 .3 days on 
average compared to 10.3 days in the control group. 
However, 2.3 acute rejections per animal still occurred) 
which in most cases led to graft failure in these 
animals. 
In the 15-DS-treated group Iv, the graft survival 
was prolonged to 20.1 days on average. Only 0.14 
acute rejections per animal and biopsy occurred) but 
severe gastro-intestinal complications and infections 
were observed, which made further experiments 
necessary to minimize these treatment related 
complications. However, by omitting azathioprine, the 
mean survival rate in the modified treatment group V 
was 35.6 days. 
In both 15-DS treated groups, a significantly 
reduced number of acute rejection and a decreased 
incidence of hyperacute rejections was noted when 
compared to the other treatment protocols. 
In conclusion, 15-DS is a promising 
immunosuppressive agent, but when given alone, graft 
survival results are not satisfactory. In combination 
with CyA, however, significant improvement of graft 
survival was achieved after cardiac and renal 
allotransplantation and after cardiac 
xenotransplantation in primates. 
After cardiac allo- and xenotransplantation) the 
number and severity of acute rejection episodes were 
significantly reduced by the addition of 15-DS. 
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After renal allotransplantation, long-term graft 
nonreactivity was observed in 50% of the animals, 
when initially treated with 15-DS and CyA. 
These findings definitely justify further studies with 




PART I: INTRODUCTION 
Ll. Immunosuppression after heart transplantation. 
Allogeneic heart transplantation (HTx) has become an accep-
ted clinical therapy for end stage cardiac diseases (1). Sufficient 
immunosuppressive therapy is, however, mandatory to avoid lethal 
rejection crises. "Conventional" immunosuppressive therapy, 
which was used for the first 10 years of cardiac transplantation, 
consisted of azathioprine, prednisone and antilymphocyte globu-
lin. Severe rejection and infection were the major cause of death, 
leading to a 1-year survival rate of only 60% after heart transplanta-
tion. The results have improved dramatically since the introduction 
of cyclosporine A-therapy (2,3). This drug is, however, not the pa-
nacea hoped for: Severe acute rejection episodes can still occur and 
represent,besides severe infections, the major cause of death follo-
wing transplantation. In addition, Cyclosporine A (CyA) has major 
side effects, such as nephro- and hepatotoxicity. A correct dosage 
schedule is therefore necessary and blood levels have to be measu-
red regularly. 
To improve immunosuppression and to reduce side effects of 
Cy A, this drug is currently combined with azathioprine and low 
dose prednisone. This drug regimen has led to an actuarial 1-year 
survival rate of 81 % after HTx for adult patients (3). This current 
immunosuppressive therapy has not yet reached the final state of 
the art, since acute rejection still occurs and severe side effects arc 
still observed. 
For these reasons, transplantation research should continue to 
concentrate on improving immunosuppressive therapy. One of the 
ideals in every field of organ transplantation would be the induction 
of tolerance against the graft; long term immunosuppressive thera-
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py would then not be necessary. As a consequence of this, not only 
allogeneic transplantation would be easily managed, but also xeno-
geneic transplantation using foreign species as organ donors would 
become possible. The need for xenogenic transplantation is beco-
ming more prominent due to the shortage of suitable donor organs 
for adult recipients as well as for small infants who are waiting for 
heart replacement. There exist several congenital heart defects 
which can be best treated with heart transplantation (e.g. hypolastic 
left heart syndrome) or even using combined heart and lung trans-
plantation. Using current immunosuppressive therapy, experimen-
tal results after xenogeneic heart transplantations are not satisfac-
tory, predominantly because of hyperacute and humoral rejection 
episodes which cannot be treated successfully at present C 4). In 
addition, further problems may be caused by infectious diseases 
(especially virus infections), which may be transmitted by the xeno-
genic donor. 
In order to improve experimental and clinical results after allo-
geneic and xenogeneic transplantation, a new immunosuppressive 
drug, 15-Deoxyspergualin 05-DS) was tested for potency and side 
effects in this study. 
1.2. 15-Deo:xyspergualin - a new immunosuppressive 
drug and its mode of action. 
15-DS is a derivative of spergualin, a guanidine-like structure. 
Its isolation from bacillus laterosporus and its anti-tumour activity 
was first described by IWASAWA et al. (5). While the exact mode of 
its immunosuppressive action is not yet fully understood, it has 
been documented that 15-DS plays an important role in antigen 
presentation and/or recognition of target antigens by effector cells: 
Within the first few days after transplantation, 15-DS reduces the 
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expression of target antigens on the transplanted cells. This pheno-
menon has been demonstrated after skin and renal transplantation 
in rodents (6). After the 3rd postoperative day, the expression of 
major histocompatibility complex class I antigens (MHC class I) on 
transplanted kidney cells completely disappeared. Since MHC class 
I structures are the most important target antigens for the response 
of cytotoxic T-lymphocytes, it is possibly imaginable that the non-
expression of these structures limits the antigen recognition by T-
effector cells (7). This action may be the first step with regard to graft 
nonreactivity. There was no influence of 15-DS on MHC class II 
expression (8). This is in contrast to the action of Cy A which affects 
the expression of MHC class II (9). When 15-DS was started on the 
4th day after transplantation, the rejection process had already start-
ed, since the expression of target antigens was not inhibited (6). 
Analysis with the Fluorescence-Activated-Cell-Sorter revealed that 
15-DS also reduces the expression of MHC class I on splenic macro-
phages. In the peritoneum, a new macrophage population was 
created, demonstrating a weaker MHC class I expression when 
compared to the original population (6); this second macrophage 
population was not induced by CyA therapy. The MHC class I and 
II expression on lymphocytes was not affected by 15-DS. These 
results confirm the different mode of action of 15-DS and Cy A. Furt-
her studies would be necessary to show whether perfusion of the 
donor organ with 15-DS results in acceptance of the graft and in 
reduction of postoperative immunosuppressive therapy. This pro-
cedure was suggested by LITTLE II et. al.who used Cy A for inhibi-
tion of alloantigen presentation in the donor organ (10). 
Already in 1987 it was reported that 15-DS suppresses the ma-
crophage function, but the exact mode of action was not under-
stood (11). These authors used the technique of chemiluminiscencc 
to demonstrate the suppression of macrophage function; the pro-
duction of oxygen derived free radicals in monocytes was inhibited 
by 15-DS (12,13). Recently it was shown that 15-DS inhibits the 
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production of Interleukin I (IL-I) by in vitro cultivated and PHA-sti-
mulated peritoneal macrophages ( 6). As a result of this process, the 
proliferation of cytotoxic lymphocytes is affected (14). This specific 
action of 15-DS is neutralized by the addition of comercially availa-
ble IL-I. TAKASU et. al. confirmed this effect of 15-DS on IL-I secre-
tion by in vitro cultivated hepatic epithelial and Kupffer cells after 
liver transplantation (15). This process might protect the transplan-
ted liver from being rejected. The ability of Kupffer cells to secrete 
IL-I, has already been described (16). In addition 15-DS might block 
the IL-I receptor on T-lymphocytes resulting in inhibition of activa-
tion (17). Already in 1979 there was evidence that treatment of ani-
mals with macrophage suppressing agents induces the prolonga-
tion of survival of transplanted pancreatic islet cells (18). 
Further reports describe the efficacy of 15-DS in treating acute 
rejection episodes after skin transplantation 09,20). An explanation 
for this may be found in its suppressive effect on macrophages (12): 
First, the presentation of antigen during the rejection process is me-
diated by phagocytosing cells (21). Second, CD4-positive 
T-lymphocytes are able to recognize their target antigen specifically 
and release cytokines which activate macrophages. These cells then 
destroy the graft, a process that can be prevented by suppression of 
their function (6,15). This "late" effect of 15-DS does, however, not 
affect the graft destruction mediated by CDS-positive lymphocytes 
which act independently of macrophages. 
A further important advantage of 15-DS lies in its specific mode 
of action which is different to that of Cy A. Because of their different 
working points, a combination of both drugs seems to be obvious. 
The function of lymphocytes (by Cy A) and macrophages (by 15-
DS) would thereby be affected resulting in a suppression of two 
immunologically essential cell populations. 
14 
Subsequently, 15-DS was shown to prolong graft survival after 
skin, heart, kidney and pancreas islet cell transplantation in rats 
(22,23,24). After renal and hepatic transplantation in particular, spe-
cific graft nonreactivity was achieved in long-term surviving rats 
(25,26). In islet cell transplantation in rats, the survival time was 
increased from a mean of 5 days to 38.3 days; in heart transplanta-
tion, from a mean of 8.5 days to 32.5 days and in kidney transplan-
tation from a mean of 7 days to more than 170 days. Especially with 
kidney transplantation in rats, the long lasting graft acceptance may 
be explained by the induction of graft tolerance. 
L3. Design of the experimental study. 
1. Very little is known about the efficacy of 15-DS in larger 
animals. In order to assess its immunosuppressive potential and 
side effects in a preclinical experiment, cardiac and renal allotrans-
plantations were performed in Chacma baboons. A special point of 
interest in this study group was the potential induction of graft spe-
cific nonreactivity using 15 DS alone or in combination with Cy A. 
2. The efficacy of this drug was also assessed in a xenogeneic 
model. Concordant cardiac xenotransplantation was performed 
using Vervet monkeys as donors and Chacma baboons as reci-
pients. In particular, the incidence of severe and hyperacute rejec-
tion episodes and graft survival rates were noted and compared 
with other irnrnunosuppressive protocols consisting either of CyA 
alone or of CyA in combination with other immunosuppressive 
agents. 
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3. In all experimental groups, parameters like frequency and 
severity of acute rejection were noted, as well as the occurrence of 
treatment related side effects. The animals were followed using 
graft biopsies, routine biochemistry of the peripheral blood and 
immunological monitoring of the peripheral blood. Graft survival 
was also compared between the different treatment groups. 
Part II 
1. 
EXPERIMENTS AND RESULTS 
15-Deoxyspergualin after cardiac and renal 
allotransplantation. 
A major aim of the study was to assess the efficacy of 15-
Deoxys pergualin (15-DS) after cardiac allotransplantation in a pre-
clinical experimental model. Since graft tolerance has been repor-
ted after renal transplantation in rodents, a comparative study using 
15-DS after renal transplantation was performed in primates as well. 
1.1. 
1.1.1. 
Experimental animals, material and methods 
Donor and recipient animals 
Chacma baboons (Papio ursinus, 10 - 15 kg body weight) ser-
ved as donors and recipients in all experimental groups. All animals 
received care according to the "Ethical Consideration in Medical 
Research, revised edition: 1987" set out by the South African Medical 
Research Council, Parow, 1989. 
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Donor and recipient animals were matched and compatible 
within the AB-blood group system. It was a precondition that donor 
and recipient animals were derived from different regions within 
South Africa in order to avoid transplantation within family mem-
bers. 
1.1.2. Anaesthesia and surgical procedure 
After premedication with Ketamine CS mg/kg b.w.), Pancuro-
nium bromide (0,2 mg/kg b.w.) and Atropine (0,5 mg), anaesthesia 
was maintained by a combination of Halothane (1 %) with oxygen 
41/min and N20 6 1/min as inhalation. 
1.1.2.1. Heterotopic cardiac transplantation 
In 27 animals, heterotopic heart transplantation in the neck 
was performed according to the technique of MANN et al. (27). 
Donor operation: 
After routine midline stemotomy, the pericardium was opened lon-
gitudinally. The inferior (IVC) and superior (SVC) vena cava, aorta 
and pulmonary artery were dissected free. Thereafter the pulmona-
ry veins were prepared. Intravenous heparin was administered (380 
U/kg). A cardioplegic cannula was inserted into the ascending aor-
ta. The SVC was ligated and the IVC clamped. The descending aorta 
was clamped and cardioplegic solution (St.Thomas solution, 15 
ml/kg b.w.) was flushed through the ascending aorta into the coro-
nary arteries. The IVC and right upper pulmonary vein were incised 
in order to avoid overdistension of the heart. In addition, the heart 
was cooled with topical cold saline solution. After perfusion with 
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cardioplegic solution, the IVC and all pulmonary veins were ligated. 
The heart was excised distally to the ligated vessels. Finally the aorta 
and pulmonary artery were dissected as distally as possible. The 
heart was placed in cold saline solution. 
Recipient operation: 
In the recipient animal, a skin incision was made anterior to the right 
stemocleidomastoid muscle. The muscle was retracted laterally and 
the carotid artery and the internal jugular vein were prepared. Par-
ticular attention was taken in order not to injure the vagus nerve. 
The carotid artery was clamped first and the aorta of the donor heart 
was anastomosed end-to-side to the carotid artery of the recipient 
by using runing 5.0 Polypropylene sutures. The internal jugular vein 
was next clamped and the pulmonary artery of the donor heart was 
anastomosed end-to-side to the internal jugular vein using running 
5.0 Polypropylene suture (Fig. 1). After removal of the clamps, two 
cannulae were inserted into the left and right ventricles in order to 
remove the air from both ventricles. The heart usually defibrillated 
spontaneously. In case of ongoing ventricular fibrillation, the hearts 
were defibrillated by using internal defibrillation paddles. After ca-
reful haemostasis, the wound was closed. As antibiotic prophylaxis, 
the animals received 500 mgAmpicillin intraoperatively and twelve 
hourly for the first postoperative day. 
1.1.2.2. Classical renal transplantation 
Altogether 25 kidneys were transplanted in the usual clinical 
manner. 
Donor operation: 
After midline laparotomy, the abdominal aorta and IVC were pre-
pared at the origin of the renal vessels. All side-branches of the renal 
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arteries and veins were ligated and dissected. After preparation, the 
NC was clamped proximally and distally to the renal veins and 
incised. The abdominal aorta was similarly clamped proximal and 
distal to the renal arteries. A perfusion cannula was inserted in be-
tween the clamps. The kidneys were perfused using Euro-Collins 
solution ( 40 ml/kg b.w.) and the kidneys were cooled with topical 
cold saline. After perfusion, both kidneys were explanted en bloc 
with the abdominal aorta and the NC still intact. The kidneys were 
placed in cold saline solution. The renal arteries and veins were 
prepared and dissected ex vivo by leaving big vessel cuffs around 
the distal ends of the vessels to facilitate the anastomoses. 
Recipient operation: 
After midline laparotomy, the right iliac region was prepared for 
implantation. The right common and external iliac arteries were 
prepared as well as the right common iliac vein. Any side braches 
were ligated and dissected. The external and internal iliac arteries 




THE TECHNIQUE OF EXPERIMENTAL 
HETEROTOPIC HEART TRANSPLANTATION 
IN THE NECK 
(MODIFIED '1FTEJ:l M'1NN ET '1L.> 






Fig. 1: Operative techique of heterotopic heart transplantation in the neck according to the technique of MANN 
(CCA • common carotio artery, UV · mtemal jugular vein, Ao - ascending aorta, PA - pulmonary artery) . 
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proximally. The common iliac artery was incised and the renal arte-
ry of the donor was anastomosed end-to-side using a running 6/0 
Polypropylene suture. Thereafter, the iliac vein was clamped proxi-
mally and distally and the anastomosis was performed end-to-side 
also by using 6/0 Polypropylene suture (Fig. 2). After release of the 
clamps, the kidney was reperfused. The ureter was than anatomo-
sed end-to-side to the bladder using the special technique accor-
ding to Gregoir to avoid urinary backflow from the bladder into the 
transplanted ureter (28). The anastomosis was performed using 7 / 0 
running Polypropylene suture. The distal portion of the ureter was 
tunnelled under the muscular layer of the bladder by using single 
4/0 Polypropylene stitches. Thereafter, the recipient's own kidneys 
were removed after the vessels and ureters were separately ligated. 
After careful haemostasis, the peritoneum and muscular layers were 
closed using running sutures. The skin was closed using interrupted 
single skin sutures. 
For antibiotic prophylaxis the baboons received 500 mg of Arn-
picillin intraoperatively and twelve hourly for the first postoperative 
day. 
20 
Fig. 2: Operative situs after classical renal transplantation. The renal artery is anastomosed to the common iliac 
artery and the renal vein to the common iliac vein. The ureter is anastomosed to the bladder tunnelled under the 
bladder muscle. 
1.1.3. Tmmunosuppressive protocol 
In this protocol, group I represents those animals following 
heterotopic cardiac transplantation, and group II the animals which 
underwent classical renal transplantation. 
The immunosuppressive protocol is listed in Table 1. Accor-
ding to this protocol, 
Groups IA (n=lO) and IIA (n=6) served as control groups and 
received no immunosuppressive medication. For group IA, a histo-
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ric control group was used which had been used for previous stu-
dies in our laboratory. 
Groups IB (n=S) and IIB (n=6) were treated with 15-DS in a 
dosage of 4 mg/kg/day, administered intravenously over a period 
of 3 hours, from postoperative day 0-9, after which immunosup-
pression was stopped. 
Groups IC (n=S) and IIC (n=S) were immunosuppressed only 
with CyA in a dosage of 10-40 mg/kg/day administered intramus-
cularly according to a whole blood trough level of 400-600 ng/ml 
from postoperative day 0-30. 
Groups ID (n=7) and IID (n=8): In this group, 15-DS was given 
in a dosage of 4mg/kg/day, adminstered intravenously over ape-
riod of 3 hours from postoperative day 0-9. In addition, the animals 
received CyA in a dosage of 10-40 mg/kg/day administered intra-
muscularly, according to a whole blood trough level of 400-600 
ng/ml from postoperative day 0-30. Thereafter no further immuno-
suppression was given. 
IMMUNOSUPPRESSIVE PROTOCOL 
Groups IA and IIA 
Groups IB und IIB 
Groups IC and IIC 
Groups ID and IID 
Control, no immunosuppression 
15-DS, 4mg/kg b.w./d i.v. from p.o.day 0-9 
Cy A, 10-40mg/kg b.w./d i.m. from p.o.day 0-30 
15-DS, 4mg/kg b.w./d i.v. from p.o.day 0-9 
and 
CyA, 10-40mg/kg b.w./d i.m. from p .o.day 0-30 








Clinical examination and graft palpation 
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Daily after transplantation, recipients were examined clinical-
ly. In the cardiac allograft group, the graft was palpated daily by the 
same person to monitor graft function. In group II, attention was 
paid as to whether the recipient animals were passing urine. It was 
not possible to exactly measure the urine output in the baboon 
cages. 
1.1.4.2. Cyto-immunological monitoring 
This method for early diagnosis of acute rejection using quali-
tative analysis of peripheral lymphocytes and their subsets has been 
described earlier (29 ,30). 
Cyto-immunological monitoring was performed 3 times weekly du-
ring the whole postoperative course. In this test, the white blood 
cells per mm3 are counted and a peripheral blood smear is prepa-
red. 
Mononuclear cells (lymphocytes and monocytes) are obtained 
from the remaining blood by centrifugation over a Ficoll Isopaque 
gradient (Ficoll Isopaque solution, density= 1.077 g/ml). Some of 
the cells obtained are spread on microscopic slides using a cyto-
centrifuge (Cytospin 1, Shandon Lab., Frankfurt, West Germany) 
and then stained with a pan optic leucocyte stain according to Pap-
penheim (May Grunwald solution, Merck Inc., Darmstadt, Giemsa 
solution, Merck Inc., Darmstadt, West Germany). 
Under a light microscope (Hellfeld microscope, Zeiss Inc., 
Oberkochen, West Germany), the cells are separated according to 
the degree of activation into normal or activated lymphocytes and 
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lymphoblasts (Fig.3). The percentage of activated lymphocytes or 
lymphoblasts per 100 lymphocytes is calculated. If more than 3% 
activated lymphocytes per 100 lymphocytes are present, the mono-
nuclear cell pattern of the recipient is described as being "activated" 
in terms of an acute inflammation process. 
Fig. 3: A typical mononuclear concentrate of the peripheral blood during an acute inflammation process: 
a) normal lymphocyte, b) activated lymphocyte, identifiable by the noticeable increase in size, pronounced 
cytoplasmic basophilia and fluffy nuclear structure; c) lympho- or immunoblast, 2-3 times enlarged, when 
compared to the normal lympoocyte; note the basophilia of the cytoplasma, nucleoli are clearly visible within 
the cell nucleus (PAPPENHEIM STAINING, Xl2SO). 
1.1.4.3. Urea and creatinine levels 
As parameters of kidney function after renal transplantation, 
serum urea and creatinine levels were measured in group II three 
times weekly. Any increase of the serum urea above 30 mmol/1 and 
of the serum creatinine above 200 mmol/1 was considered signifi-
cant and a sign of impaired graft function. 
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1.1.4.4. Transmyocardial and renal core biopsies 
At weekly intervals, transmyocardial biopsies were performed 
in group I and renal core biopsies in group II. For this procedure, 
the animals were briefly anaesthetised (Ketamine 5 mg/kg b.w., 
halothane 1 %, oxygen 4 I/min and N20 6 I/min) and a small skin 
incision was made above the transplanted organs. The biopsies 
were performed using a trucut biopsy needle. Using this method, 
relatively large samples were obtained by cutting through the whole 
left ventricular myocardial wall or through half the renal core. The 
biopsy samples were stored in formaldehyde and evaluated histolo-
gically. 
Acute rejection was graded according to the University of Cape 
Town grading system (30). This is a semi-quantitative scoring sy-
stem which gives the clinician an easily understood guide as to the 
severity of rejection. Rejection is categorized as mild, moderate or 
severe. During mild rejection, only perivascular or interstitial mono-
nuclear cell infiltration is observed but without myocardial cell da-
mage. During moderate and severe rejection, cell infiltrates are pre-
sent in addition to myocardial cell necrosis. The latter rejection 
episodes require rejection treatment after clinical heart transplanta-
tion. 
Figures 4, 5, and 6 show typical examples of mild, moderate 
and severe rejection after cardiac allotransplantation. A similar sco-
ring system may be used for renal allotransplantation (Figs. 7, 8, 9). 
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Fig. 4 : Mild acute rejection episode: perivascular and scanty interstitial mononuclear cell infiltrations, slight 
interstitital oedema, but no sign of myocyte damage. Figs. 4-9 and 19-22 were generously supplied by Professor 
Alan Rose. 
Fig. 5: Moderate acute rejection: Diffuse interstitial mononuclear cell infiltration, more pronounced interstital 
oedema and signs of myocyte necrosis . 
Fig. 6: Severe acute rejection: In addition to the mononuclear cells, there is infiltration of neutrophile 
granulocytes, diffuse myocyte necrosis and haemorrhage. 
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Fig. 7: Mild renal rejection: Perivascular lymphocytic infiltrates and only scanty interstitial mononuclear cell 
infiltrates are visible. 
Fig. 8: Moderate renal rejection: There is mononuclear cell infiltration with evidence of acute tubular necrosis . 
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Fig. 9 : Severe renal rejection: Diffuse lymphocytic and neutrophile granulocyte cell infiltration with signs of 
haemorrhage and diffuse acute tubular necrosis are obvious. 
1.1.4.5. Autopsy 
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In both groups I and II, the experiments were terminated in the 
event of graft failure or when the animals died of any other compli-
cation. After cardiac transplantation, graft failure was evident when 
there was loss of palpable graft function. After renal transplantation, 
uraemia and hyperkalaemia terminated the survival and indicated 
graft rejection. 
At the end of each experiment, the animals underwent full 
autopsy to evaluate the exact cause of death or of graft failure. In 
addition, samples of all organs were taken in order to look for tre-




Statistical significance was calculated using the Log Rank ana-
lysis and the Student-t-Test. 
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1.2. Results 
1.2.1. Graft survival 
1.2.1.1. Graft survival after heterotopic cardiac 
transplantation 
The survival rates for group I are listed in Fig. 10 and Table 2 
and 3. 
Animal no. Date of tx Date of death Survival ( d) Cause of death 
GROUP IA: 
1 5 rejection 
2 6 rejection 
3 6 rejection 
4 9 rejection 
5 9 rejection 
6 10 rejection 
7 10 rejection 
8 16 rejection 
9 17 rejection 
10 22 rejection 
GROUP IB: 
222 29-09-88 17-10-88 18 rejection 
180 20--06-88 12-07-88 22 graft ischaemia• 
152 09-05--88 06-06-88 28 rejection 
1&5 04-07--88 04-08-88 31 rejection 
173 06-06-88 18--07-88 42 Diarrhoea + emaciation 
GROUP IC: 
313 16-05-88 21-05-88 5 rejection 
316 16-05-88 04-06-88 18 rejection 
317 23-05-88 05-07-88 43 organized thrombus 
319 23-05-88 06-07-88 47 rejection 
323 26-05-88 14-07-88 49 rejection 
GROUP ID: 
277 09-02-89 14-02-89 5 rejection 
254 10--11-88 27-11-88 17 unknown 
236 27-10-88 05-12-88 39 rejection 
262 24-11-88 04-01-89 41 graft ischaemia• 
224 13-10-88 12-12-88 6o rejection 
257 17-11--88 25-01-89 67 rejection 
289 07-03-89 19-05-89 73 rejection 
Table 2: Number of ex~rimental animal, date of transplantation, date of death, survival time and cause of death 
after cardiac allotransp antation (• see text) . 
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After heterotopic cardiac transplantation, the control group 
which received no immunosuppression (group IA), showed a 
mean graft survival rate of 11.0 ± 1.8 days. Treatment with 15-DS 
alone (group IB) for postoperative days 0-9 improved the mean 
graft survival rate to 28.2 ± 4.1 days; this was statistically significant 
when compared to the control group (p < 0.05). 
Therapy with CyA (group IC) for postoperative days 0-30 led to a 
graft survival rate of 32.4 ±8.8 days on average (p <0.05 vs. control). 
CARDIAC ALLOTRANSPLANf ATION (Group I) 
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Fig. 10: Survival rates for the different treatment groups after heart transplantation. Increased graft survial is 
already apparent with 15-DS treatment alone (group IB). The best graft survival was achieved in group ID 
05-DS and CyA), when compared to the control group IA. 
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The combination of 15-DS (for postoperative days 0-9) with CyA 
(for postoperative days 0-30, group ID) prolonged graft survival 
further to 43.1± 9.6 days on average (p < 0.025 vs. control). 
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Group IA m IC ID 
GSR (d) 11.0 ± 1.8 28.2 ± 4.1* 32.4 ± 8.8* 43.1 ± 9.6** 
• p <0.05 vs. control 
•• p < 0.025 vs. control 
Table 3: Mean graft survival rate (GSR) in days after heterotopic cardiac (group O allotransplantation. 
1.2.1.2. Graft survival after renal transplantation 
The graft survival rates after renal transplantation are shown in Fig. 
11 and Tables 4 and 5. 
Animal no. Date oftx Date of death Survival (d) Cause of death 
GROUP IIA: 
150 09-05-88 16-05-88 7 organized thrombus 
189 04-07-88 12-07-88 8 uraemia + hyperkalaemia 
174 o6-o6-88 17-06-88 11 uraemia + hyperkalaemia 
211 11-08-88 24-08-88 13 uraemia 
160 23-05-88 06-06-88 14 uraemia + hyperkalaemia 
179 20-o6-88 11-07-88 21 uraemia 
GROUP IIB: 
291 07-03-89 12-03-89 5 uraemia + hyperkalaemia 
268 09-02-89 15-02-89 6 uraemia 
223 29-09-88 08-10-88 9 uraemia + hyperkalaemia 
160 23-05-88 02-06-88 10 ureamia 
150 09-05-88 19-05-88 10 diarrhoea + emaciation 
174 o6-o6-88 17-06-88 11 uraemia + diarrhoea 
GROUP UC: 
329 30-05-88 05-06-88 7 uraemia 
315 23-05-88 10-07-88 19 uraemia 
320 23-05-88 20-07-88 29 unknown 
326 30-05-88 16-07-88 48 uraemia 
314 16-05-88 04-07-88 49 uraemia 
GROUPIID: 
263 24-11-88 04-12-88 10 uraemia 
265 24-11-89 05-12-89 11 unknown 
249 10-11-88 28-11-88 18 uraemia 
226 13-10-88 10-11-88 28 uraemia 
225 13-10-88 25-04-89 194 uraemia 
292 07-03-89 274 alive 
279 23-02-89 286 alive 
267 01-12-88 370 alive 
Table 4: Number of experimental animal, date of transplantation, date of death, survival time and cause of death 
after renal allotransplantation. 
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The control group which received no irnmunosuppression 
(group IIA) showed a mean graft survival rate of 12.3 ±2.1 days. 
Treatment with 15-DS alone (group IIB) did not influence graft sur-
vival positively when compared to the control (8.5 ±1.0 days). 
Group IIA IIB IIC 11D 
GSR (d) 12.3 ± 2.1 8.5 ± 1.0 30.4 ± 8.2 148.9 ± 52.7** 
** p < 0.025 vs. control 
Table 5: Mean graft survial rate (GSR) in days after renal (group m allotransplantation. 
Treatment with CyA alone (group IIC) improved graft survival to 
30.4 + 8.2 days on average (p = n.s. vs. control). 
However, the combination of 15-DS ( for postoperative days 0-9) 
and CyA (for postoperative days 0-30, group IID) again prolonged 
graft survival even further to 148.9 ± 52.7 days on average with 3 
animals still alive 274, 286 and 370 days after transplantation (p < 
0.025 vs. control) at the time of writing. 
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RENAL ALLOTRANSPLANf ATION (Group II) 
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Fig. 11: Survival rates after renal transplantation. Only group IID 05-DS and Cy A) showed a significant increase 
in survial time when compared to the control group IIA. 3 primates are still alive 370, 286 and 274 days after 
surgery; 1 baboon died 194 days after transplantation. 
1.2.2.1. causes of experiment termination and side effects 
after heterotopic cardiac transplantation 
The experimental endpoints in the different treatment sub-
groups after cardiac transplantation are listed in Fig. 12. 
In the control group IA, acute rejection was the cause of graft failure 
in all cases. 
In group IB, one of 5 animals died of severe diarrhoea and emacia-
tion, probably the result of 15-DS treatment. The remaining grafts 
stopped functioning due to acute rejection in 3 cases and graft 
ischaemia in 1 case. At histology, graft rejection as the cause of the 
described graft ischaemia could not be excluded. 
In group IC, acute rejection again was the dominant cause of graft 
failure. In 1 case, an organized thrombus near the venous anasto-
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mosis led to termination of graft function. 
In the combination treatment group ID, acute rejection was respon-
sible for graft failure in 4 out of 7 cases. One unexplained cause of 
death was noted 60 days after surgery. In the 1 case with graft 
ischaemia, graft rejection as the cause could also not be excluded. 
Acute Rejection 10/10 
Organised thrombus 
1/5 
Acute Rejection 4/5 
GROUP IA 
GROUP IC 
GI Complications 1/5 
lschaemla 1/5 
Acute Rejection 3/6 
COD? 1/7 
lschaemla 1/7 
Acute Rejection 4/7 
GROUPIB 
GROUP ID 
Fig. 12: Experimental endpoints after heart transplantation. Most grafts stopped functioning due to acute graft 
rejection. One animal in group IB died from gastrointestinal complications probably due to 15-DS therapy. 
Regarding treatment related side effects, except for the 1 ani-
mal with diarrhoea and emaciation, no lethal treatment related side 
effect was seen. No major infections occurred among the treated 
animals, minor wound infections being excluded. Postoperative 
weight loss, which was noted in all treated animals, was not diffe-




Causes of experiment termination and side effects 
after renal transplanation 
The causes of experiment termination after renal transplanta-
tion are shown in Fig. 13. 
In the control group IIA, uraemia and hyperkalaemia as a result 
of acute graft rejection was the cause of death in most cases. 
In group IIB, 2 out of 6 animals died of gastrointestinal compli-
cations associated with diarrhoea and emaciation, probably as a 
result of 15-DS treatment; one animal was not uraemic at this time. 
Uraemia and hyperkalaemia were the cause of death in the remai-
ning 4 cases. 
In group IIC, graft rejection was again the dominant cause of 
graft failure in 4 out of 5 cases. One animal died 48 days after trans-
plantation of unknown cause. 
In group IID 50% of the animals ( 4 out of 8) died due to graft 
rejection. One animal died 194 days after surgery and no cause of 
death was found clinically or at autopsy. Three out of the 8 reci-
pients are still alive at the time of writing 274,286 and 370 days after 
transplantation. 
In common with observations found after cardiac transplanta-
tion, treatment related side effects occurred only in animals treated 
with 15-DS alone (group IIB). These lethal gastrointestinal compli-
cations of diarrhoea and emaciation were probably the result of 
15-DS treatment. The autopsy showed a nonspecific enterocolitis in 
these animals. In the combination group IID no such side effects 
were seen. Again in the whole experimental group, no major infec-
tion was seen, minor wound infections were excluded. 
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With regard to weight loss after transplantation, animals trea-



























Fig. 13: Experimental endpoints after renal allografting. Uraemia and hyperkalaemia as a result of acute graft 
rejection were the dominant causes of death in groups IlA and IIB. 2 animals in group IIB died from gastro-
intestinal complications. 3 out of 8 animals of group !ID are still alive (COD? - unknown cause of death). 
1.2.3. Number of acute rejection episodes 
A rejection episode was defined as such by the histological 
result of the myocardial or renal biopsy. 
In order to compare the figures, the number of acute rejection 
episodes per animal was calculated in relation to every biopsy as 
well, because the animals had different survival periods (n = 
nAR/animal x biopsy). 
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A difficulty arose in defining the rejection episode because the 
biopsy was taken routinely at weekly intervals. It is possible that the 
first biopsy may have shown evidence of acute rejection and that 
histological evidence of rejection one week later may in fact reflect 
on-going rejection rather than sequential episodes of rejection. It 
would have been impossible without taking biopsies every day 
(which was not feasible) to differentiate between on-going rejec-
tion and different rejection episodes. It is believed that the demon-
strated calculation allows best the comparison of frequency and 
evaluation of rejection within the different groups. 
1.2.3.1. Number of acute rejection episodes after 
heart transplantation 
For this calculation, only moderate and severe rejection episo-
des were taken into consideration. In this situation, myocardial cell 
damage will be seen at histological examination and would lead to 
rejection treatment in a clinical situation. No biopsies were taken in 
the control group (Table 6). 
As detected by myocardial biopsies, the number of rejection 
episodes were significantly reduced in the cardiac transplant group 
ID treated with 15 DS and Cy A (0.08 vs. 0.17 acute rejections /biop-
sy/animal, p = 0.013, group ID vs. IB, Table 4). The single treatment 
groups IB and IC did not differ with regard to the number of acute 
rejections/animals and biopsy 
Group IA m IC ID 
nAR/animal - 0.17 0.14 0.08* 
biopsy 
* p = 0.013 vs. 1B 
Table 6: Number of acute rejection episodes per animal and biopsy after cardiac (group I) transplantation. The 
number of rejection episodes per animal was calculated in relation to every biopsy, because the animals had 
different survival periods. 
1.2.3.2. Number of acute rejection episodes after 
renal transplantation 
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After renal transplantation the number of acute rejection epi-
sodes per animal and biopsy between the different treatment 
groups was not significantly different (Table 7). Again, only mode-
rate and severe rejection episodes were taken into consideration. 
Group 11A IIB IIC DD 
nAR/animal - 0.23 0.18 0.15 
biopsy 
Table 7: Number of acute rejection episodes per animal and biopsy after renal (group II) transplantation. 
1.2.4. Cyto-immunological monitoring 
In order to compare the different groups, absolute numbers of 
activated lymphocytes were calculated per mm3. 
The number of total lymphocytes/mm3 is calculated by using the 
total white blood cell count/mm3 and the percentage of lymphocy-
tes among the white blood cells. The number of activated lympho-
cytes per mm3 is then calculated by using the percentage of activat-
ed lymphocytes/100 lymphocytes and the total number of 
lymphocytes/mm3. 
1.2.4.1. Cyto-immunological monitoring after heart 
transplantation 
Figure 14 shows the absolute number of activated lymphocy-
tes before and during acute rejection as detected by myocardial 
biopsies. Cyto-immunological monitoring was only done in the 15-
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DS treated groups; thus, no such monitoring was done in the control 
group IA and group IC. 
In both 15-DS treated groups IB and ID a significant increase of 
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Fig. 14: Cyto-immunological monitoring after cardiac transplantation. In the treatment groups IB and ID, a 
significant increase of activated lymphocytes within the mononuclear concentrate o f the pe riphe ral blood was 
noted during acute rejection (p<0.05). 
The increase of activated lymphocytes during rejection under 
CyA immunosuppression has been shown in earlier studies (31). 
1.2.4.2. Cyto-immunological monitoring after renal 
transplantation 
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Similarly, after renal transplantation an increase in the absolute 
number of activated lymphocytes was noted in the control group 
and 15-DS treated groups during rejections proved by biopsy. How-
ever, this increase turned out to be significant only in the combina-
tion treatment group IID (p = 0.023; Fig. 15). No cyto-immunolo-
gical monitoring was done in the CyA-treated group IIC. 
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Fig. 15: Cyto-immunological monitoring after renal transplantation. During acute rejection an increase o f 
activated lymf>hocytes within the mononuclear concentrate of the peripheral blood was also noted . Howeve r, 
the increase of these activated cells proved not to be significant except for group IID (P<O.OS). 
1.2.5.1. Urea levels after renal transplantation 
The serum urea levels of all treatment subgroups after renal 
transplantation are shown in Figure 16. 
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An initial rise of serum urea within the first 6 days after trans-
plantation was seen in all treatment groups. In the control group IIA 
and the 15-DS treated group IIB, the levels increased even more 
during the later follow-up. 
In the CyA-treated group UC, and particularly in the combina-
tion treatment group IID, the levels returned to normal again within 
the first 10 days and stayed low for the whole postoperative period 
in the long-term survivors. These data show a normal renal function 
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Fig. 16: Urea levels after renal transplantation. After an initial postoperative rise, the levels returned to 
acceptable levels again in groups ITC and IID. 
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1.2.s.2. Creatinine levels after renal transplantation 
The creatinine levels are demonstrated in Figure 17. Like the 
urea levels, there was an initial rise of serum creatinine in all treat-
ment groups within the first 4 postoperative days after transplanta-
tion. 
Once again the control group IIA and the 15-DS treated group 
IIB showed a further increase in serum creatinine, demonstrating 
ongoing graft rejection and failure. 
Within the CyA treated group IIC and the combination treat-
ment group IID, the creatinine levels returned to nearly normal le-
vels within the first 10 days after transplantation. In the long-term 
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Fig. 17: Creatinine levels after renal allografting. In groups IIC and ITD, these levels dropped again after an initial 
postoperative rise. 
44 
A comparison of serum creatinine levels before and during 
acute rejection episodes was done in the control group IIA and the 
15-DS treated groups IIB and IID (Fig.18). A rise of serum creatinine 
was noted in groups IIA and IIB during acute rejection. Relatively 
high creatinine levels as a sign of impaired renal function may indi-
cate acute rejection episodes even before rejection is evident within 
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Fig. 18: Creatinine levels before and during acute rejection after renal transplantation. Except in the combination 
treatment group IlD, a rise of creatinine was noted during acute renal rejection episodes. 
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1.2.6. Induction of graft nonreactivity 
After cardiac transplantation, long-term graft non-reactivity 
was not achieved in either of the subgroups IB, IC and ID. However, 
the occurrence of a delayed rejection was noted in group ID. Four 
out of 6 animals in this group lived with no sign of rejection up to a 
mean of 21.8 days, counted from the time treatment was disconti-
nued. The best survivor lived 40 days with no sign of rejection after 
therapy was stopped (Table 8). 
After renal transplantation, a 9-day treatment period with 15-
DS alone did not show any short or long term graft tolerance. 
Graft nonreactivity was observed only in group IID, which was 
treated with a combination of 15-DS and CyA. In this group, 4 out 
of the 8 animals were graft tolerant up to 340, 256, 244 and 164 days 
after immunosuppression was discontinued. The first 3 of those 
animals were still alive at the time of writing, 1 animal died due to 
unknown reason 194 days after transplantation. 
GRAFf NON-REACTIVITY 
Group ID 4/6 animals with no sign of rejection up to a mean of 21.8 days after 
treatment discontinuation 
Group IID 4/8 animals were graft tolerant up to 340, 256, 244 and 164 days after 
treatment discontinuation 
Table 8: Induction of graft norueactivity after heart (group I) and kidney (group II) transplantation. 
In order to explore the nature of this graft tolerance, the 3 long-
term survivors received a third party skin graft in the later follow-up 
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(1st baboon: 252 days, 2nd baboon: 214 days, 3rd baboon: 133 days 
after the first transplantation). All animals rejected these skin grafts 
within 1 week after implantation (5, 6 and 7 days). The histopatho-
logy showed evidence of acute cellular rejection, such as mononu-
clear and polymorphnuclear cell infiltrations and tissue necrosis. 
At the same time they did not reject their transplanted kidneys. 
Thus, these data are suggestive of donor graft specific nonre-




Current research in the field of organ transplantation should 
aim at a reduction of the incidence of acute rejection and of treat-
ment related side effects without increasing the risk of infection. 
Various new immunosuppressive drugs are being currently te-
sted for their potency and side effects (11,32,33). 
Remarkable results have been achieved when using the new 
immunosuppressive drug 15-DS after various transplant proce-
dures in rodents (11,22,23). 15-DS, given in a dosage of 2.5 
mg/kg/day, increased graft survival significantly after allogeneic 
heart, kidney and pancreas islet cell transplantation in rats. Little 
information exists concerning its efficacy in larger animals. In dogs, 
for example, it has been reported that equivalent dosages of 15-DS 
cause severe side effects such as diarrhoea and emaciation (34,35). 
Reduction of dosage and/ or combination with other drugs, such as 
steroids or Cy A, improved the efficacy of 15-DS and reduced its side 
effects (34,36). 
In a project on skin transplantation in monkeys, however, the-
se primates seemed to tolerate dosages of 15-DS in a similar way to 
rodents (37); survival rates superior to those achieved with CyA 
were observed in this model. 
Stimulated by these results, 15-DS was tested for its potency, 
efficacy and side effects for the first time in a primate model after 
heart and renal allotransplantation, as an ideal preclinical experi-
ment. 
The number of animals in each group is obviously small, being 
limited by the availability of primates. However, care was taken to 
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perform enough experiments in order to compare the different 
groups statistically. 
In our study, 15-DS was given alone or in combination with 
CyA after cardiac (group I) and renal (group II) allotransplantation 
in Chacma baboons. 
15-DS was used as an immunosuppressive agent in a dosage 
of 4 mg/kg/day for 10 days starting on the day of operation, as 
recommended by DICKNEITE et al., who used the same drug after 
skin transplantation in monkeys (37). Exact dosage and toxicity in-
vestigations with 15-DS exist so far only for the rodent model (6). 
Reduction of the 15-DS dosage below 2.5 mg/kg/d led to a signifi-
cant decrease of graft survival time after skin and renal transplanta-
tion. The duration of treatment also seems to be of importance. 
Studies in rodents revealed that treatment with 15-DS for less than 
10 days resulted in inferior survival rates after skin and renal trans-
plantation (6). This was confirmed by WALTER et al. who recom-
mended a minimum duration of at least 10 days after kidney trans-
plantation in rats (38). 
Groups IA and IIA served as control groups and received no 
immunosuppression. In groups IB and IIB, 15-DS was used for 
postoperative days 0-9 C 4mg/kg/day) only and then stopped. 
In groups IC and IIC, CyA was administered alone (10-40 
mg/kg/day) for the first 30 postoperative days. In groups ID and 
IID, 15-DS from postoperative day 0-9 was combined with CyA 
from postoperative day 0-30; thereafter, no further immunosup-
pression was given. 
After cardiac transplantation, 15-DS alone led to a significant 
prolongation of graft survival from 11.0 days to 28.2 days on average 
(p < 0.05 vs. control). This confirms a previous report which descri-
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bes an increase of transplant survival after heart transplantation in 
rodents using 15-DS (23). CyA alone also achieved an improved 
survival rate of 32.4 days on average (p < 0.05 vs. control). 
When 15-DS was combined with Cy A, mean graft survival im-
proved to 43.1 days on average (p < 0.025 vs. control), with the 
longest animal living up to 75 days after transplantation, 45 days 
without any immunosuppression. The additive effect of 15 DS and 
Cy A is also described in recent studies after pancreatic transplanta-
tion in rats; this drug combination allowed even lower dosages of 
both drugs to be used (39). 
A recent study performed at the University of Cape Town com-
pared two new immunosuppressive agents, FK 506 and Rapamy-
cin, in a similar model after heterotopic cardiac allotransplantation 
in primates (33). FK506 and Rapamycin are both microlide antibio-
tics with immunosuppressive properties. Their success has also 
been reported after various transplant procedures also in primates 
(32). The primates in this study received either FK506 or Ra pamycin 
for 14 days, either intravenously or intramuscularly. The mean sur-
vival rates were 86.8 days on average using FK506 i.m. and 49. 7 days 
using FK506 i.v. Intramuscular Rapamycin achieved an average sur-
vival of 17.7 days on average and 37.7 days when given i.v. These 
results demonstrate that Rapamycin, when adminstered i.v., achie-
ved similar results to those which were obtained using 15-DS. 
FK506 treated animals seemed to have a superior outcome. How-
ever, one must emphasize that the animals in the mentioned study 
were treated for acute rejection in contrast to our study using 15-DS, 
where rejection episodes were not treated. 
Following renal transplantation, 15-DS alone did not improve 
survival when compared to the control group. This confirms studies 
after renal transplantation in dogs, when no clear benefit of 15-DS 
alone was discernible (35). The exact reason for this phenomenon 
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is not yet known. When used as a sole immunosuppressive agent, 
the effect of 15-DS is definitely dose-dependant (36). A higher do-
sage of 15-DS could thus eventually have improved the results. But 
when 15-DS is combined with other immunosuppressive agents, 
like CyA, the additive effect of both drugs allows lower dosages to 
be used (39). 
CyA alone led to an expected improved survival rate of 30.4 
days on average; however, this proved not to be significant when 
compared to the control group. 
The combination of 15-DS with CyA again showed a strong 
additive effect. A mean graft survival of 148.9 days was achieved 
(p< 0.025 vs. control), with 3 animals still alive at the time of writing. 
This is the first time, such excellent survival has been reported using 
the described drug combination in a primate model. Previous stu-
dies confirming the additive effect of 15-DS and CyA were perfor-
med only in rodents (39). These results in primates are far superior 
to those described using the same drug combination of Cy A and 
15-DS after renal transplantation in dogs (35). 
Concerning the question of severe treatment related side ef-
fects , one of the primates in group IB and 2 of the animals in group 
IIB, died due to gastrointestinal complications. Stool specimens 
were sent for microbiological examination with no positive results. 
The autopsy showed an unspecific enterocolitis in those animals, 
possibly as a result of drug toxicity. Similar effects have been obser-
ved when using 15-DS after transplantation in dogs (34,35). General 
side effects (nausea, diarrhoea and weight loss) were noticed after 
renal transplantation in dogs using a dosage of 1.2 to 4.0 mg/kg/d 
(35,36,40) and after renal xenotransplantation (fox to dog) with 2.5 
mg/kg/d given intravenously (41). A delayed start of 15-DS treat-
ment and further dose reduction has been described as being able 
to reduce the occurrence of these side effects even further (37). 
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Measuring blood levels of 15-DS would certainly be desirable, but 
such a test was not available yet at the time of the study. 
Further haematological studies revealed that 15-DS induced 
leucopenia and anaemia (42,43), an inhibition in the maturation of 
bone marrow cells ( 44) and a decrease in number of bone marrow 
cells ( 44) after transplantation in rodents. Toxicity studies in these 
animals showed that these haematological side effects of 15-DS ap-
peared only when a dosage of more than lOmg/kg/day was used 
(6). In our own experiments, no leucopenia or anaemia was obser-
ved in the long term follow up; no bone marrow studies were per-
formed for this reason. 
When 15-DS was combined with CyA no general side effects 
were observed, although the same dosage of 15-DS was used in 
both groups. The combination of both drugs showed not only a 
strong synergism with regard to graft survival, but apparently also 
prevents the animals from developing the previously described 
nonspecific enterocolitis; this was observed after cardiac and renal 
transplantation. No major infection occurred among our experi-
mental animals. 
15-DS in combination with CyA influenced the frequency of 
acute rejection after heart transplantation: In group ID the number 
of acute rejection episodes per animal was significantly reduced 
when compared to the 2 groups treated with either CyA or 15-DS 
alone. As explained above, the term rejection episode does not al-
ways reflect single episodes of short duration, but might well repre-
sent longer ongoing rejections. Thus the described results allow 
comparison of frequency and duration of acute rejection. 
In another study, to be described later, after xenogeneic heart 
transplantation in primates, we were also able to decrease the num-
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ber of severe acute rejection episodes using a combination of 15-DS 
and Cy A ( 45). 
However, since rejection was not treated in our protocol, the 
observed rejection episodes did not resolve spontaneously, but 
caused termination of graft function at some stage in all experimen-
tal groups. 
Cyto-immunological monitoring of the peripheral blood was 
used as a noninvasive parameter to detect acute rejection episodes. 
In bothlS-DS-treated groups IB and ID, a significant increase of 
activated lymphocytes in the mononuclear concentrate of the peri-
pheral blood was noted during acute rejection episodes after cardi-
ac transplantation. This confirms earlier studies using Cy A immuno-
suppression, when cyto-immunological monitoring was also able 
to diagnose acute rejection episodes after heart transplantation (31). 
In our study using 15-DS treatment, the acute inflammatory process 
during acute cardiac rejection episodes was also visible within the 
mononuclear concentrate of the peripheral blood. 
This increase of activated lymphocytes during rejection was also 
noted after renal transplantation in groups IIA, IIB and IID, but did 
not gain statistical significance in all these groups. This phenome-
non may be based on the fact that lymphocytes which are activated 
within the graft do not all recirculate into the blood, but are excreted 
into the urine as well. This phenomenon has been used to detect 
renal rejection episodes - activated lymphocytes are noted at urine 
cytology ( 46). 
Postoperative urea and creatinine levels were monitored to 
assess the function of the transplanted kidney in group II. In the 
control group and the group treated with 15-DS alone, levels never 
reached normal values, but increased further until final graft rejec-
tion and failure occurred. 
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However, in the Cy A treated group and particularly in the com-
bination treatment group IID, these levels returned to nearly normal 
levels within a few days after transplantation and stayed low for the 
whole postoperative period in the long-term survivors, repre-
senting normal renal function after transplantation. 
During acute rejection, a rapid increase of serum creatinine 
was noted. This confirms that monitoring of creatinine levels is a 
useful diagnostic hint for renal graft rejection. 
The most important finding in this study, however, was the 
induction of graft specific nonreactivity after renal transplantation. 
This nonreactivity may be defined as the indefinite survival of 
an allograft with normal function and without the necessity for the 
permanent administration of immunosuppressive drugs. At an im-
munological level, tolerance should be specific. This means that the 
recipient must be unresponsive to the relevant allograft alone, and 
immunological reactivity to other foreign antigens or third party 
grafts must be maintained. 
Using 15-DS treatment, the phenomenon of graft tolerance has 
so far been reported only in the rat model after heart, kidney and 
liver transplantation (25,26,47); after renal transplantation, all trans-
planted rats remained graft tolerant after initial treatment with 2.5 
mg/kg/day 15-DS given for the first 10 postoperative days (26). The 
combination of 15-DS and Cy A also achieved tolerance after rat-tail 
skin transplantation, a model which is very susceptible to acute 
rejection ( 48). 
In our primate heart transplant model, long-term graft nonre-
activity was not achieved in any of the treatment groups. However, 
delayed rejection occurred in group ID within a mean of 21.8 days 
after treatment discontinuation. The occurrence of graft nonreacti-
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vity has recently been reported when using FK506 after heterotopic 
cardiac transplantation in primates (33). When FK506 was admini-
stered intramuscularly for 14 days after transplantation, 2 out of 5 
grafts still showed excellent function 138 and 110 days after 
immunosuppression had been stopped. 
Using the combination of 15-DS and Cy A after renal transplan-
tation, however, long-term non-reactivity was achieved in 4 out of 
8 animals (500/o). These 4 animals remained graft tolerant up to 340, 
256, 244 and 164 days after immunosuppression had been discon-
tinued completely. 
In order to explore the nature of this graft tolerance, the 3 long 
term survivors received a third party skin graft in the later follow up. 
The animals rejected these skin grafts within one week without 
affecting their transplanted kidneys. From these observations, one 
may assume evidence of donor graft specific nonreactivity after in-
itial treatment with 15-DS and Cy A. An ideal proof of this specific 
graft nonreactivity would be the re-acceptance of grafts from the 
original donor animal. This, however, was not possible in our expe-
riments, because the original donor animals served as heart donors 
as well at the time of their explantation. 
An immunological explanation for this phenomenon of graft 
nonreactivity in vivo has not yet been worked out in vitro, since the 
exact mode of graft tolerance after transplantation is still not fully 
understood. 
One theory of tolerance induction is the elirnination·of a parti-
cular cell clone by the tolerogenic substance ( 49). 
Other authors advance their theories according to the pheno-
menon of neonatally induced tolerance and showed that this early 
form of non-reactivity is mediated by suppressor cells (50). These 
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suppressor cells abolish rejection of grafts bearing specific donor 
antigens with high efficiency. In addition, suppressor-cell mediated 
graft tolerance was induced by various immunosuppressive agents 
like ALG according to THOMAS and CARVER (51) and even by Cy A 
according to KUPIEC-WEGLINSKI (52). Confirmation that these 
suppressor cells are T-cells resulted from surface labelling studies 
which showed that they carried the T-cell antigen (53). However, 
these cells are not marked by the usual suppressor/ cytotoxic cell 
marker and this specific suppressor action is not removed by deple-
tion of the suppressor/ cytotoxic cell population (54). These data 
clearly differentiate the suppressor cells of transplantation tolerance 
from suppressor T-cells operating in responses to conventional 
(non-transplantation) antigens. 
It is known that 15-DS affects macrophage function and inhi-
bits clone expansion of lymphocytes during acute rejection (55); 
however, 15-DS does not inhibit the suppressor cell function and 
these cells may be responsible for maintenance of immunologic 
nonreactivity (56). The synergistic effect of CyA may be explained 
by its relatively sparing action on suppressor cells (57). 
The exact mode of graft nonreactivitywas discussed in a study 
after renal transplantation in rats, where 15-DS treatment induced 
graft tolerance in 100% of the transplanted animals ( 6). Specific non-
reactivity was achieved in this study as well, while third party grafts 
were rejected. However, this long lasting graft survival was not 
achieved after skin transplantation in the same model. This may 
reflect the different immunological response to various transplan-
ted organs, since in our study we also achieved different results after 
cardiac transplantation. 
As described before, 15-DS plays an essential role in antigen 
presentation and/ or recognition of target antigens after transplanta-
tion (see chapter I.2.). Using immunohistological studies, the de-
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crease of MHC class I-expression after 15-DS therapy could well 
explain the nonreactivity after renal transplantation in rats (6); since 
MHC class I antigens are the most important target antigens for cy-
totoxic T-cells, non-expression of these structures limits the antigen 
recognition by T-effector cells. 
In addition, 15-DS inhibits the release oflnterleukin 1 from the 
antigen presenting cells. Allospecific T-helper cells are able to re-
cognize the alloantigen, but fail to respond due to the lack of the 
signal IL-1. One of the consequences may be "clonal anergy" as a 
mechanism of specific nonreactivity (58). 
Suppressor MLC-studies after renal transplantation in rats 
using 15-DS treatment demonstrated that unspecific suppressor 
cells are responsible for functional graft tolerance in the early phase 
after transplantation and donor-specific suppressor cells in the late 
phase (6). This analysis of cell mediated nonreactivity was confir-
med in various transplantation models in rats using CyA after liver 
transplantation (59) and 15-DS after renal (60), skin (17) and liver 
transplantation (61). 
These suppressor cells influence the induction of the immune 
response with effect against MHC class I and class II antigens (62, 
63). In addition to the effect on the immune response, the activation 
and differentiation of effectorT-lymphocytes is suppressed (64) . 
Since the early nonreactivity is maintained by unspecific sup-
pressor cells, one may conclude that these cells are responsible for 
the inhibition of the immune response; the specific suppressor cells, 
however, would account for the effect on effector T-lymphocytes. 
Both effects may, if permanent absence of the immunological reac-
tion results, lead to graft tolerance. The nonreactivity just described 
can develop spontaneously, without the use of an immuno-
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suppressive agent (65). In case of stronger histoincompatibility, this 
is only achieved by the use of drugs like Cy A (59) or 15-DS (60). 
Similar results with regard to graft nonreactivity following renal 
transplantation in primates have also been described when total 
lymphoid irradiation has been applied (66). In this model using 
irradiation, evidence for suppressor cell mechanisms seems to have 
been obtained; so called "natural suppressor cells" inhibit the gene-
ration of cytotoxic T-cells, but allow the emergence of antigen-spe-
cific suppressor T-cells (66). The authors were able to demonstrate 
a donor-specific T-cell mediated suppression in appropriate cocul-
ture experiments. As in our experiments, third party grafts were 
rejected in an unmodified acute fashion, while the original kidney 
allografts remained unaffected. Further data on allograft acceptance 
have been published by THOMAS et al., who used the combination 
of posttransplant antithymocyte globulin and donor bone marrow 
infusion after renal transplantation in rhesus monkeys (67). In Tho-
mas' series the percentage of long-term nonreactive primates was 
38% (57). A possible explanation offered for this graft acceptance is 
the presence of apparent bone marrow suppressor/cytotoxic cells 
of donor origin in the long term functioning kidneys (68). 
The described incidence of 50% graft non-reactivity after renal 
transplantation following initial treatment using 15- DS and Cy A is 
very encouraging. These findings justify further experimental eva-
luation using 15-DS, particularly in combination with CyA in order 







The issue of xenotransplantation has become more and more 
prominent because of the lack of suitable human donor organs. This 
scarcity of donors is compounded further by the fact that transplan-
tation of the heart may be necessary as an emergency procedure. 
There is a clearly defined need for heart transplanation in neonates 
and infants. Severe cardiac defects, such as hypoplastic left heart 
syndrome, have a poor prognosis after conventional cardiac surge-
ry, but organ procurement for neonates remains a major problem. 
The use of anencephalic infant donors raises additional ethical and 
legal restrictions (69). For these children, the only biological option 
to an allogeneic graft is therefore a xenogeneic donor heart. 
In the case of adults, there is little evidence, as yet, that trans-
plant laws or specific regulations have done anything to improve 
the supply of donor organs (70). Due to the increased demand for 
donor organs, there is no doubt that there is a need for xenotrans-
plantation. Cooperation with ethic commitees and the media is im-
portant in order to persuade the public to accept the fact that the 
lives of animals will be sacrificed in order to save human lives. 
2.1.1. Concordant-discordant xenotransplantation 
The occurrence of acute rejection episodes is largely depend-
ent on the genetic homogeneity between donor and recipient. With 
greater donor-recipient genetic disparity, the onset of such acute 
rejection mechanisms becomes more acute, often occurring within 
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minutes of transplantation - predominantly when donor and reci-
pient are members of different orders. Such early hyperacute rejec-
tion involves humoral responses (74). The terminology of concor-
dant and discordant xenotransplantation was proposed by CALNE 
as a means of distinguishing between potentialy successful grafts 
(concordant model, e.g. Vervet monkey - baboon), in which rejec-
tion is largely cellular, and unsuccessful grafts (discordant model, 
e.g. pig- baboon), in which antibody-dependent, early hyperacute 
rejection occurs (72). In addition to this definition, there seems to 
be a restriction of hyperacute rejection to specific organs, since the 
liver may not be hyperacutely rejected in a given species combina-
tion, while the kidney and heart are (73). 
In distinguishing between concordant and discordant models, 
the presence of preformed natural cytotoxic antibodies, as deter-
mined by a cytotoxic crossmatch, as well as high mixed lymphocyte 
reaction, is of greater importance than assumptions based on 
phylogenetic comparisons (72). Unfortunately, the target antigens 
of hyperacutely rejected grafts are not known. There may be a cross-
reaction with donor MHC antigens or with entirely different antigen 
systems that may be species specific or shared between related spe-
cies in the "concordant" system. 
60 
2.1.2. Rejection mechanisms 
The distinguishing feature of graft rejection in xenotransplan-
tation as opposed to allotransplantation is the action of preexisting 
humoral antibodies: graft destruction results from immunoglobulin 
binding to vascular endothelium and subsequent activation of both 
the complement and platelet aggregation system. This, in tum leads 
to thrombosis and severe ischaemic damage (7 4). 
This may result in early hyperacute rejection with features of 
oedema, myocyte necrosis, microvascular thrombi and interstitial 
haemorrhage due to vascular disruption. 
The exact pathways are described as follows: During hypera-
cute rejection, the vaso-occlusive and -destructive changes precede 
the appearance of neutrophil granulocytes, which then progressi-
vely accumulate (75) and the cellular infiltrate is completed by the 
appearence of macrophages. 
Complement activation by preformed humoral antibody is the 
essential prerequisite for initiation of hyperacute rejection. 
Graft binding of C3 is a consistent immunohistological conco-
mitant of hyperacute rejection (76). Complement activation could 
induce marked vasoconstriction, directly lyse endothelial targets 
and generate vasoactive related agents (77). 
Microvascular blockage by platelet-fibrin thrombi has been 
emphasized as an early and cardinal feature of hyperacute rejection 
(78). Vascular occlusion with resultant hypoperfusion and graft 
ischaemia could be the central determinant of this kind of graft re-
jection. Thus, although hyperacute rejection is clearly initiated by 
antibody-dependent complement mediated mechanisms, the pos-
sibility remains that immune-mediated activation of platelets and 
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the coagulation cascade within the grafts could be the proximate 
effector mechanism of graft rejection (74). 
In concordant xenograft models, like the Vervet monkey/ba-
boon model, levels of species specific preformed natural antibodies 
are observed less often than in discordant models. In earlier expe-
riments at the University of Cape Town, it has been shown that the 
presence of preformed natural antibodies did not necessarily corre-
late with early hyperacute rejection (71). 
However, accelerated graft rejection is characteristically obser-
ved in concordant xenotransplantation (73). In the hamster to rat 
model, low levels of heterophile immunoglobulin molecules do not 
usually give rise to early hyperacute rejection but, instead, induce 
specific features of the rejection process (79):By 3 days, interstitial 
oedema and focal infarction occur together with a neutrophilic in-
filtrate. Late rejection was associated with a mixed cellular infiltrate, 
prominent arteritis and arteriolitis with fibrinoid necrosis and arte-
riolar thrombosis, progressive interstitial haemorrhage, and 
widespread myocardial cell necrosis; microvascular thrombi are 
missing. 
Accelerated rejection appears to be associated with a certain 
humoral response, although cellular immune mechanisms may be 
involved to a variable degree (73). 
Concordant xenotransplantation between closely related spe-
cies, such as interprimate combinations, appears to most closely 
simulate allograft rejection (80,81). There is, as yet, no evidence that 
the cellular part of the response is quantitatively or qualitatively 
different from allograft rejection. In addition, however, a distinctive 
arteritis was observed, occuring as early as 1 day post transplanta-
tion. This vasculitis seems to be primarily induced by humoral im-
mune mechanisms. Later, myointimal proliferation and obliterative 
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arterial sclerosis complete the picture of vascular damage. This, 
also, is not very different from allogeneic heart transplantation, sin-
ce obliterative coronary artery disease is the major cause of late graft 
failure (82). 
These studies demonstrate that there is a chance of successful 
immunosuppression in the concordant xenotransplant model, sin-
ce the rejection mechanisms are not that different to the allogeneic 
response, when compared to the discordant system. 
2.1.3. Design of the experimental study 
In order to avoid early hyperacute rejection, as it occurs in 
discordant xenograft models, a concordant xenograft model was 
chosen by using Vervet monkeys as donors and Chacma baboons 
as recipients. 
In order to do research relevant to the clinical situation, prima-
tes were used as experimental animals in this study. E. KEMP has 
recommended the primates as an ideal model for xenotransplanta-
tion, since the apes are phylogenetically and immunologically the 
species nearest to man and it seems possible to extrapolate the re-
sults to the clinical situation (83). They have ABO antigens which 
are easily assayed and are large enough to enable repeated graft 
biopsies to be taken. 
The genetic relationship between different species is based on 
the similarity in structural and organizational development of the 
DNA (84). According to RAKE, it was shown in reassociation expe-
riments and DNA-DNA-hybridisation that 9So/o of human DNA can 
be found in the genes of chimpanzees, 92% in other old world mon-
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keys (e.g. vervet monkeys and baboons) and85% in asiatic primates 
(85). While the numeric differences in nuclein acids may be small, 
differences in genes and genetic control mechanisms are so obvious 
that they clearly distinguish between such closely related species 
such as man and ape (86,87). 
With regard to evolution studies, the genetic disparity of vervet 
monkeys and baboons is comparable with the system homo sa-
piens - chimpanzee. 
Another very important point is that baboons and Vervet mon-
keys are still plentiful in Southern Africa, and these animals are re-
latively easy to maintain and breed under laboratory conditions. 
The major aim of this research protocol was to optimize immu-
nosu ppressive therapy after xenogeneic transplantation. CyA, in 
addition to its wellknown use in allogeneic transplantation, has also 
been used in order to prolong graft survival after xenogeneic trans-
plantation (88,89,90). For example, MICHLER et al. demonstrated a 
12-fold prolongation of mean cardiac xenograft survival to 77 days 
using parenteral Cy A and steroids (91). 
The present study shows the influence of different immuno-
suppressive drug combinations with CyA on xenograft survival, as 
well as on occurrence and number of hyperacute and acute cellular 
rejection episodes. 
A particular point of interest was the combination with a new 
immunosuppressive agent, 15-Deoxyspergualin with its previously 
described anti-macrophage activity. The success of anti-macropha-
ge agents after xenotransplantation has been described earlier (92). 
CHAUSSY et al. compared the efficacy of anti-macrophage serum 
(AMS) with ALG after allogeneic and xenogeneic skin and kidney 
transplantation. AMS increased xenograft survival more significant-
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ly with an improved function of the renal xenografts. Histologically, 
the cellular infiltration of both grafts was delayed and the humoral 
response was decreased. The authors demonstrated indirect evi-
dence for the importance of the macrophage in the immune respon-
se to xenogeneic tissue and the probable requirement for proces-
sing of xenogeneic antigen by host antigen presenting cells. 
In addition, the possibility of clinical xenotransplantation is 




Experimental animals, material and methods 
Donor and recipient aoima1s 
Vervet monkeys ( Cercopithecus aethiops) weighing 2 to 6 kg 
served as donors in our xenograft model. Chacma baboons (Pa pio 
ursinus) weighing 10 to 15 kg were used as recipients. 
Vervet monkeys and baboons have human type A, B and H 
antigens expressed on their tissues and in secretions while their sera 
regularly contain reciprocally related anti-A and anti-B isoaggluti-
nins (93). The distribution of ABO blood groups in both species are 
as follows: About one third of baboons tested are blood group A, 
one third group B, and one third group AB. In vervet monkeys, a 
high frequency of blood group A is observed (94). Group O is very 
rare in both species (95). 
The donor and recipient animals were matched and compati-
ble within the AB blood group system. 
65 
Screening for preformed antibodies was not done, since it has 
been shown that species specific reactions between vervet mon-
keys and baboons are weak or erratic (94). 
In previous experimental studies using primates, no correla-
tion was found between positive pretransplant crossmatch tests and 
graft survival (96). Although such testing would be desirable, parti-
cularly in the clinical situation, it involves a considerable amount of 
work for an immunological laboratory and, since previous studies 
did not show a positive correlation with the experimental results, 
we refrained from pretransplant crossmatch testing in this study. 
All animals received care according to the "Ethical considera-
tion in medical resarch, revised edition: 1987" set out by the South 
African Medical Research Council, Parow, 1989. 
2.2.2. Anaesthesia and surgical technique 
After premedication with Ketamine (5 mg/kg b.w.), morphine 
(0,25 mg/kg b.w.), pancuronium bromide (0,2 mg/kg b.w.) and 
atropine (0,5 mg), anaesthesia was maintained with a combination 
of halothane (1%), oxygen 41/min and N20 61/min as inhalation. 
The operative technique of heterotopic heart transplantation 
in the neck, using the technique of MANN et al., has already been 
described in detail in chapter 1.1.2.1. 
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2.2.3. Immunosuppressive protocol 
Depending on immunosuppressive regimes, the following 
groups were studied (Table 9): 
Group I (n=8) served as a control group with no irnrnunosup-
pression given. A historic control group from earlier studies in our 
laboratory was used for this purpose. 
Group II (n=5) received CyA given in a dosage of 20 to 40 
mg/kg/day administered intramuscularly, according to a whole 
blood trough level aimed between 400 and 600 ng/ml. CyA was 
combined with azathioprine (2.5 mg/kg/ day) andmethylpredniso-
lone (0.3 mg/kg/day tapered down to 0.2 mg/kg/day within 3 
weeks). 
Group III (n=6): In addition to the drug regimen of group II, 
rabbit antithymocyte globulin (RATG, Fresenius, Frankfurt, West 
Germany) in a dosage of 9 - 15 mg IgG/kg/day was given i.v. for 
postoperative days 0-4. 
Group IV (n= 7): In this group, the triple-drug regimen of group 
II consisting of cyclosporine A (Cy A), azathioprine and methylpred-
nisolone, was combined with 15-Deoxyspergualin (15-DS, 3 
mg/kg/day administered intravenously for postoperative days 0-4 
and 2 mg/kg/day for postoperative days 5-9). Due to severe treat-
ment related side effects which were observed in this treatment 
group, the immunosuppression was later modified as follows: 
In group V (n=5), 15-DS (4 mg/kg/day administered intrave-
nously for postoperative days 0-9), was combined with CyA and 
methylprednisolone only, and azathioprine was omitted. In addi-
tion the infusion time of 15-DS was prolonged to 3 hours of conti-
nuous intravenous infusion. 






control, no immunosuppression 
CyA 20-40 mglkgld, aza 2.5 mglkgld, mp 03 mglkgld 
CyA + aza + mp + RATG 9-15 mg IgG/kg/d, p .o.d 0-4 
CyA + aza + mp + 15-DS 3 mglkgld (p.o.d 0-4), 
2 mglkgld (p.o.d 5-9) 
CyA + mp+ 15-DS 4 mglkgld (p.o.d 0-9) 
Table 9: Immunosuppressive protocol in the different groups after heterotopic cardiac xenotransplantation 
(aza- azathioprine, mp- methylprednisolon). 
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Acute rejection episodes were treated with 500 mg methyl-
prednisolone intravenously for 3 to 5 consecutive days in groups II 
- V. 
As antibiotic prophylaxis, all animals received 500 mg of Am-





Graft palpation and clinical examination 
Every day after transplantation, the graft function was checked 
and the heart was palpated by one specific person. In addition, the 
animals underwent a full clinical examination. 
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2.2.4.2. Cyto-immunological monitoring 
Three times weekly, blood samples were taken for routine 
haematological, biochemical and cyto-immunological monitoring. 
The latter test was performed in groups II, III and N. 
The technique of cyto-immunological monitoring has been ex-
tensively described in chapter 1.1. 4. 2. 
The percentage of activated lymphocytes per 100 lymphocytes 
was calculated and served as a diagnostic hint for acute rejection 
episodes. 
2.2.4.3. Transmyocardial biopsies 
At weekly intervals, transmyocardial biopsies were perfor-
med. For this procedure, the animals were briefly anaesthetized 
(Ketamine 5 mg/kg, Halothane 1%, N20, 02) and a small skin inci-
sion was made above the transplanted heart. The transmyocardial 
biopsy was then performed using a trucut biopsy needle and a who-
le transmyocardial biopsy was taken through the left ventricular 
wall. 
The biopsies were evaluated histologically. The following ty-
pes of rejection reactions were seen: 
Acute rejection episodes were divided into 3 groups according to 
the histopathology (81): 
1. Acute cellular rejection: Perivascular and interstitial mono-
nuclear cell infiltration combined with interstitial oedema and/or 
presence of myocyte necrosis (Fig. 19). 
Fig. 19: Acute cellular rejection after cardiac xenotransplantation: A similar picture occurred as after 
allotransplantation: Mononuclear cell infiltration occurs perivascularly and in the interstitium, in combination 
with myocyte necrosis and interstitial oedema. 
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2. Hyperacute rejection: The typical morphological changes 
include microvascular thrombi, endothelial cell necrosis, and wide-
spread interstitial haemorrhages throughout the graft, accompanied 
bya polymorphonuclearcellular infiltration (Figs. 20,21). The resul-
ting vascular obstruction and destruction rapidly lead to serious 
malfunction of the graft and ischaemic changes will become recog-
Fig. 20: Hyperacute rejection after xenogenic transplantation: inlerstitial haemorrhage and interstitia oe ema IS 
seen without any mononuclear cell infiltrate . 
71 
Fig. 21: Macroscopic picture of hyperacute rejection; note the swelling of the heart and the haemorrhage on the 
surface. 
3. Mixed rejection: The biopsy findings in this group show 
features of both the acute cellular and hyperacute type of rejection 
(Fig. 22). Thus, a distinction between acute cellular and hyperacute 
rejection is not always clear cut, and mixed forms may occur. In our 
study, frequently neither form of rejection was uniform. In some 
microscopic fields only one form of rejection was seen, in other 
areas only the other form, and in some fields both forms, were seen 
in juxtaposition. The late onset of the hyperacute component of 
mixed rejection also differs from the classical concept of early hy-
peracute rejection. 
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Fig. 22: Mixed type of acute rejection after xenogeneic transplantation. In addition to the features of hyperacute 
rejection demonstrated above, typical signs of cellular rejection such as mononuclear cell infiltrations are seen as 
well. 
2.2.4.4. Autopsy 
At the end of each experiment, the animals underwent full 
autopsy in order to confirm the cause of death and to look for treat-
ment related side effects by histological examination of all organs. 
2.2.5. Statistics 
Statistical significance was calculated in accordance with the 






The experiments were terminated whenever the grafts stop-
ped functioning or when the animal died of any other complication. 
The survival rates for the different groups are listed up in Figure 23 
and Tables 10 and 11. 
Animal no. Date oftx Date of death Survival (d) Cause of death 
GROUP I: 
844 1 hyperacute rejection 
837 6 severe acute rejection 
843 9 severe acute rejection 
841 10 severe acute rejection 
839 11 unknown 
855 12 severe acute rejection 
811 17 hyperacute rejection 
829 18 severe acute rejection 
GROUP II: 
858 05-03-87 11-03-87 6 hyperacute rejection 
842 06-03-87 16-03-87 11 severe acute rejection 
005 29-01-87 09-02-87 11 severe acute rejection 
857 17-03-87 30-03-87 14 unknown 
868 17-04-87 10-06-87 53 severe acute rejection 
GROUP III: 
065 20-07-87 14-08-87 25 severe acute rejection 
023 11-05-87 10-06-87 30 severe acute rejection 
006 26-05-87 02-07-87 37 severe acute rejection 
044 17-o6-87 31-07-87 44 unknown 
015 19-05-87 05-07-87 47 pulmonary infection 
025 20-05-87 05-08-87 77 diarrhoea and emaciation 
GROUP IV: 
103 19-10-87 20-10-87 1 hyperacute rejection 
087 14-09-87 27-09-87 13 diarrhoea and emaciation 
097 05-10-87 21-10-87 16 pulmonary infection 
088 21-09-87 09-10-87 18 severe acute rejection 
090 23-09-87 13-10-87 20 diarrhoe and emaciation 
098 06-10-87 11-11-87 36 severe acute rejection 
094 28-09-87 04-11-87 37 pulmonary infection 
GROUPV: 
112 16-11-87 01-12-87 15 pulmonary infection 
113 20-11-87 22-12-87 32 mixed rejection 
116 27-11-87 31-12-87 34 mixed rejection 
125 16-02-88 03-04-88 47 mixed rejection 
Table 10: Number of experimental animal, date of transplantation, date of death, survival time and cause of death after cardiac 
xenotransplantation. 
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Fig. 23: Xenograft survival rates for the different treatment groups. The best graft survival rate was achieved with 
a combination of Cy A, azathioprine, methylpredniso lone and RATG (group III). The termination of graft survival 
within the first 2 postoperative days always corresponded to the occurrence of hyperacute rejection. 
The control group I with no immunosuppression, had a mean 
graft survival of 10.3 ± 5.4 days. 
Treatment with CyA, azathioprine and methylprednisolone 
(group II) led to a mean graft survival of 19.0 ± 21.8 days and show-
ed no significant difference to the untreated control group (Table 
8). 
The addition of RATG to the immunosuppressive protocol 
(group III) led to a significantly higher survival time of 43.3 ±18.5 
days (p < 0.005 vs. control). The most successful experimental ani-
mal lived for 77 days after transplantation. 
The combination of the basic drug regimen with 15-DS (group 
IV) also increased the graft survival rate to 20.1 ±11.5 days (p <0.05 
vs. control). The omission of azathioprine in this drug regimen con-
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sisting now of Cy A, Methylprednisolone and 15-DS (from postope-
rative day 0-9) improved graft survival even more to 35.6 +- 14.2 
days on average (p <0.01 vs. control group, Table 11). 
Groups I II III IV 
GSR 10.3 19 43_3••• 20.1· 
(days) ±5.4 ±21.8 ±18.5 ±11.5 
••• p < 0.05 •• p < 0.01 * p < 0.05 
Table 11: Graft survival rate (GSR) in days after cardiac xenotransplantation within the different groups. 
2.3.2. causes of experiment termination and 




The causes of experiment termination are graphically shown 
in Figure 24. 
In groups I and II, cellular and hyperacute graft rejection were 
the dominant causes of graft failure in 890/o and 80% of the animals 
respectively. When RATG was added (group III), acute rejection 
terminated the graft function in 50% of the cases, while infections, 
diarrhoea and other complications such as thrombosis of the graft 
anastomosis or renal failure were the cause of death in the remai-
ning 50%. 
The combination of the triple-drug regimen with 15-DS led to 
a high incidence of lethal complications, such as infections and di-
arrhoea in 57% of the animals. The remaining 43% of the experi-
ments were terminated due to graft rejection. 
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Omission of azathioprine (group V) showed fewer treatment 
related side effects; 80% of the animals were sacrificed due to the 
graft rejection and only 20% died of infections. 
XENOGENIC HEART TRANSPLANTATION 





















Fig. 24: Causes of experiment termination shown graphically in a pie diagram. Rejection (hyperacute, cellular or 
mixed) was the dominant cause in groups I and II, while infections and gastrointestinal complications occured 
mainly in groups III and IV. In group V, less lethal treatment related side effects were seen. 
77 
2.3.3. Number of acute rejection episodes 
The number of rejection episodes per animal and biopsy was 
calculated for each group and is listed in Table 12. In order to com-
pare the figures, the number of acute rejection episodes per animal 
was calculated in relation to every biopsy as well, because the ani-
mals had different surival periods (n = nAR/animal x biopsy). 
In group II, an average of 0.53 rejection episodes per animal 
and biopsy was observed. In group III, the group with the longest 
survival rate, still 0.4 acute rejections per animal and biopsy were 
nevertheless observed and had to be treated. 
The results were significantly different in the 15-DS treated 
groups. In group IV only 0.14 graft rejection episodes occurred per 
animal and biopsy (p <0.05 group IV vs. group III). In group V, also 
only 0.14 rejections per animal were observed, although survival 
and observation period is similar to group III (p < 0.05 group V vs. 
group III). 
Groups I II m IV V 
nAR - 0.53 0.40 0.14* 0.14* 
* p < 0.05 vs. group III 
Table 12: Number of acute rejections in each treatment group. In group N and group V only 0.14 rejections per 
animal and biopsy were observed. These numbers differed significantly from the results obtained in group III 
(p < 0.05, AR-acute rejection episode). 
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2.3.4. Histopathology of acute rejection 
In the control group I, hyperacute rejection was seen in 
33.3%, mixed rejection in 55.6% and cellular (acute) rejection in 
11.1 % of biopsies (Fig. 25). This means, in nearly 90% of all biopsies, 
there were at least some features of rejection in the biopsy findings. 





























Fig. 25: Histopathology of the myocardial biopsies. Most of the biopsy findings in groups I, II and III showed 
evidence of rejection; in groups N and V, 72.7% and 61.S % of the results were normal with no sign of acute 
rejection. 
In the treated groups II, III and N, hyperacute rejections occur-
red less frequently. In group II, only 14.3% of the rejections were 
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hyperacute and 21.4% of mixed type. Twenty-one point four per-
cent of rejections were of the cellular type and 42.991> of the biopsies 
turned out to be normal. In group III, hyperacute rejection occurred 
in only 10.8% of biopsies, cellular rejection in 35.1% and mixed 
rejection in 40.5%. Despite the longest survival rate, only 18.5% of 
the biopsies showed normal myocardium with no evidence of re-
jection. 
In both 15-DS treated groups 4 and 5, the majority of all biopsy 
samples were normal and showed no sign of rejection. In group IV, 
72.7% of the biopsies showed normal myocardium, and only 4.5% 
hyperacute rejection occurred. 18.2% of the rejections were of cel-
lular and 4.5% of mixed origin. In group V, 61.5% of the biopsies 
were normal, while 19.2% showed rejections of the cellular type 
and 19.2% rejections of the mixed type (Fig.25). 
2.3.5. Cyto-immuoological monitoring 
The results of the cyto-immunological monitoring showing the 
percentage of activated lymphocytes per 100 lymphocytes before, 
during and after rejection episodes are shown in Figure 26. A5 men-
tioned above, this test was performed in the treated groups II, III 
and IV. 
In those groups, a significant rise of activated lymphocytes per 
100 lymphocytes was noted whenever an acute rejection episode 
was diagnosed by biopsy; in group II from 2.5% to 4.6% (p=0.0125), 
in group III from 3.2% to 5.9% (p=0.0014), in group IV from 2.0% to 
4.4% (p=0.0071). The decrease in the number of activated lympho-
cytes after successful rejection therapy was clearly evident and did 
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not show any statistical difference when compared to the pre-rejec-
tion level. 
XENOGENIC HEART TRANSPLANTATION 
CYTOIMMUNOLOGICAL MONITORING 
~ ACTIVATED LYMPHOCYTES 
9 --.------------------------------, 
p • 0.0014 
4 
2 .... 
GROUP II GROUP Ill GROUP IV 
mffl PRE-AR - AR ~ POST-AR 
Fig. 26: Results of the cyto-immunological monitoring after xenogenic transplantation. All acute rejection 
episodes in the treated groups II, III and N were accompanied by a significant rise of activated lymphocytes 
within the mononuclear concentrate of the peripheral b[ood (AR- acute rejection episode). 
These data confirm that cyto-immunological monitoring is a 
reliable method to diagnose acute rejection after xenotransplanta-




During the last 30 years, xenogeneic transplantation has beco-
me a more and more interesting field in research, the aim being to 
optimize immunosuppressive therapy. 
2.4.1. Experimental xenotransplantation 
Cyclosporine, in addition to its well known use in allogeneic 
transplantation, has also been described as prolonging graft survi-
val in the xenogeneic model (88,89,90). 
Before Cy A became available, conventional immunosuppres-
sive drugs like azathioprine, steroids or antilymphocyte globulin 
(ALG) were used to avoid graft rejection. 
DUBERNARD and DONAWICK described ALG being able to 
prolong renal,cardiac and skin xenograft survival in an experimen-
tal model (97 ,98). The ability of ALG to prolong survival of renal 
xenografts in large animals was described by BRENDEL et al. who 
used fox-to-dog and wolf-to-dog xenograft combinations (99). The 
best results with equine-ALG were achieved, when the recipient 
was first desensitized against horse serum proteins. PERPER et al. 
studied the ability of ALG to prolong pig renal xenografts in goat 
recipients (100). Of great interest was the histological evidence sug-
gesting that ALG substantially alters the mechanism of graft rejec-
tion. Without ALG treatment, the features of xenograft rejection 
consisted of cellular and humoral components. ALG was able to 
ablate the mononuclear cell response, while the humoral compo-
nents, like interstitial haemorrhage and vascular disruption, re-
mained uninfluenced. 
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The effect of Cy A on xenograft survival has been described 
controversially. HOMAN et al. were able to extend the survival of 
hamster hearts, transplanted heterotopically into rats, only by 
applying toxic dosages of Cy A (88). In the hamster to rat xenograft 
model, suppression of mainly humorally mediated rejection episo-
des was only achieved by Cy A in combination with splenectomy of 
the recipient (101). 
In contradistinction, BAILEY et al. have described significant 
increase in survival of lamb hearts in newborn goats with the use of 
Cy A (102). MICHLER et al. reported a 12-fold prolongation of graft 
survival after xenogeneic cardiac transplantation in primates using 
parenteral Cy A and steroids (91). Although both cellular and humo-
ral mechanisms were involved in the rejection process, these episo-
des were reversible with increased immunosuppression. The histo-
logical appearances were notable for the absence of accelerated 
transplant atherosclerosis. The same group has published a compa-
rative study between heterotopic and orthotopic cardiac grafts 
( 114). The good results achieved with Cy A and particularly with the 
addition of RATG in the heterotopic could not be repeated in the 
orthotopic group. This could mean that in closely related species, 
minimal or moderate rejection does not really affect the function of 
a heterotopic graft, but could lead to failure of the orthotopic heart 
in its function to support the entire circulation. Thus, results achie-
ved in heterotopic heart transplant models should only with caution 
be transfered to the orthotopic situation. 
Experiments carried out in the fox/ dog model have shown an 
improvement in heterotopic heart xenograft survival time using im-
munosuppression with CyA in combination with methylpredniso-
lone (89). In several other experimental studies, the positive effect 
of Cy A has not been confirmed and it has been suggested that the 
success of CyA is dependent on the various animal species being 
used (103). 
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As another form of immunosuppressive therapy, selective 
lymphoid irradation (TII) was reported to be effective after cross-
species transplantation, particularly when combined with ALG 
(104). 
During TLI treatment, there is a significant decrease of the total 
lymphocyte count. After completion of a TLI course the absolute 
lymphocyte count begins to recover (105). It has been clearly de-
monstrated, however, that the T-cell count remains diminished for 
many years after TII. Suppressor/cytotoxic cells will slowly reach 
pretreatment levels again whereas helper/inducer T-cells remain 
decreased (106). Thus TLI creates a reversed helper/suppressor cell 
ratio. TLI has been successfully used after allotransplantation and 
excellent results have been achieved by MYBURGH et al. after renal 
transplantation also in humans (107). 
The mechanism of action also explains the possible effect of 
TLI after xenotransplantation. TLI as monotherapy, however, did 
not show a positive influence on xenograft survival in rodents ( 104). 
The combination of Cy A and TLI led to a prolongation of heart 
xenograft survival in the hamster/rat model (108); graft survival was 
greater than 100 days in most of these animals. In our own labora-
tory experience, when the combination of Cy A and TII was used in 
primates, the occurrence of rejections was decreased significantly, 
but severe treatment related complications were the major cause of 
death in the experimental animals (109). 
In the present study, cross-species heterotopic heart transplan-
tation was performed in the concordant model using Vervet mon-
keys as donors and Chacma baboons as recipients. A concordant 
model was chosen due to the disappointing results after discordant 
xenotransplantation (110). Using pigs as donors and baboons as 
recipients, early hyperacute rejection occurred within minutes after 
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perfusion of the transplanted organs. Absorption of the donor spe-
cific preformed natural antibodies by perfusion of donor kidneys 
on the recipient circulation, resulted only in temporary delay of 
early hyperacute rejection, with termination of graft function occur-
ring 4 or 5 days subsequently. In order to avoid this early complica-
tion, a concordant model was chosen in this study. 
In our Vervet monkey/Chacma baboon model, levels of spe-
cies specific preformed natural antibodies were observably less 
than with the pig/baboon model, with notable posttransplant in-
creases in antibody titre being exhibited in only a small fraction of 
the recipients (71). This preformed natural antibody presence did 
not correlate with early hyperacute rejection, although hyperacute 
rejection can still be observed in this model, occurring as early as 
within the first 24 hours after implantation. 
A further prec,ondition of our study was AB blood group com-
patibility between donor and recipient. The Vervet monkey and 
baboon species share the AB blood groups with the human race 
and reciprocal natural anti-A and anti-B antibodies are regularly 
present. As mentioned before, the proximity in genetics and immu-
nology of these primates justify their use for a preclinical research 
project (111). The A and B antigens of the AB genetic system in the 
Chacma baboon and Vervet monkey are not expressed on the ery-
throcyte, but are present on the vascular endothelium and can thus 
be identified as a target antigen by the immune system (112). In 
another study performed at our own laboratory, heterotopic cervi-
cal xenografts were performed between AB-compatible and -in-
compatible pairs (113). Survival was increased in the compatible 
group and the incidence of hyperacute rejection was also decreased 
in the compatible group compared to the AB-incompatible group. 
However, these results did not gain statistical significance. Because 
of these results, AB-compatibility was a precondition in our experi-
mental model. 
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In this study, CyA was used in different drug combinations to 
enhance optimal immunosuppressive therapy. 
A particular point of interest was the effect of 15-DS on xenograft 
outcome. 
Graft survival rate, frequency and histopathological features of re-
jection episodes and the occurrence of treatment related side effects 
were taken into consideration. 
The combination of Cy A with Azathioprine and Methylpredni-
solone did not show a significant increase in xenograft survival rate 
in this model. These findings confirm those by SADHEGI et al. who 
used a similar experimental model in primates (114). 
When Cy A was used as monothera py after xenogeneic skin 
transplantation in rodents, no significant prolongation of graft sur-
vival was achieved using three different dosages of Cy A ( 115). From 
these experiments one may conclude that Cy A will have a positive 
effect only when combined with other immunosuppressive agents. 
In our primate experiments, the triple-drug regimen with the 
addition of rabbit antithymocyte globulin (RATG), however, led to 
a highly significant prolongation of experiment duration of 43.3 
days on average as compared to 10.3 days in the untreated control 
group (p < 0.005 vs. control). A recent publication by MICHLER et 
al. confirms the success of this drug regimen including RATG after 
xenotransplantation in primates (111). The previously mentioned 
study by SADHEGI et al. (114), did not confirm this finding particu-
larly after orthotopic transplantation. However, the main difference 
between the two experimental models is that in our study acute 
rejections were treated with steroids to make the experiment as 
close to clinical transplantation as possible. 
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The success of RATG therapy after xenotransplantation has 
already been described by THOMAS et al who used this drug after 
mouse-to-rat skin transplantation (115). Graft survival was prolon-
ged significantly and equally impressive was the low level of toxici-
ty of this drug. The degree of inflammatory reaction and the vigour 
of rejection was diminished, resulting in prolongation of graft sur-
vival (115). 
The ability of RATG and Cy A to synergize as immunosuppres-
sive agents after allotransplantation has been described previously 
(116). One of the important findings by the THOMAS' group was 
that RATG was able to prolong xenografts more effectively than 
even toxic doses of CyA (115). One possible explanation is that 
RATG may act to ablate antibody-dependent cell-mediated cytoto-
xicity (ADCC) which has been shown to be operative in xenografts 
(117). The effector cells mediating ADCC are suppressed by RATG 
because these cells express surface antigen determinants in com-
mon with T-lymphocytes and are thus destroyed or blocked by 
RATG (118). In addition, RATG has some anticomplementary acti-
vity which may contribute particularly to the suppression of hype-
racute xenograft rejection (115). Thus, it is not astonishing that 
RATG particularly in combination with other immunosuppressive 
agents is able to prolong xenograft survival. 
The use of 15-DS instead of RATG showed a less significant 
increase in survival of 20.1 days on average (p <0.05 vs. control). 
In the THOMAS series after xenogeneic skin transplantation in 
rodents, 15-DS as monotherapy given in three different dosages was 
not able to prolong graft survival significantly (115). 15-DS, how-
ever was very toxic; the overall death rate from toxicity was 66% 
when given in a dosage from 5-10 mg/kg/d. However when com-
bined with RATG in this model, the combination was very success-
ful (119). Interestingly enough, this drug combination was the most 
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successful regimen used in the THOMAS series (115). There exist 
even other positive reports using 15-DS after xenogeneic heart 
transplantation in rodents, where this drug was able to increase 
transplant survival significantly (120). Also in the fox/dog model, 
15-DS was able to prolong graft survival after renal transplantation 
C 41). Thus, these controversial reports may indicate that the effect 
of 15-DS after xenotransplantation may be organ and/or species 
specific. Several effects of 15-DS, such as the suppression of ILl 
secretion and expression of MHC class I antigens on macrophages, 
and the decrease of the plaque-forming response may easily ex-
plain its effect also after xenotransplantation (121). 
Omission of azathioprine and modification of the dosage of 
15-DS resulted in an improved survival time of 35.6 days in group 
V (p < 0.01 vs.control). Graft survival in this group was not signifi-
cantly different from results achieved in the group with RATG 
(group III). 
Graft rejection was the main cause of experiment termination 
in the untreated control group I and in group II treated with CyA, 
azathioprine and methylprednisolone (89% and 81% resp.), which 
confirms the latter regimen as being insufficient immunosuppres-
sion after xenogeneic transplantation (103). 
In group III (33%) and particlarly in group IV (53%), infections 
and severe treatment related side effects, such as diarrhoea and 
emaciation, were the main reasons for termination of the experi-
ments. As after cardiac and renal allotransplantation, autopsy revea-
led nonspecific enterocolitis in these animals. The stool specimen 
sent for microbiological examination, were all negative apart from 
the usual enteral flora. This high rate of complications occurring in 
group IV led to a modification of the 15-DS protocol in group V. 
Omission of azathioprine and combination of 15-DS with Cy A and 
methylprednisolone only, resulted in a decrease of treatment rela-
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ted side effects and thus provided a significant prolongation of ani-
mal survival time. Diarrhoea is a well known side effect of azathio-
prine; therefore the combination of 15-DS and azathioprine increa-
ses the incidence of this fatal side effect. In the clinical situation, in 
contrast to the experimental setup, this complication may be treated 
successfully by parenteral hyperalimentation and enteral abstinen-
ce. 
The most prominent finding in group N and group V was the 
fact that 15-DS was able to reduce the number of hyperacute and 
acute cellular rejection episodes significantly to only 0.14 rejection 
episodes per animal and biopsy (p < 0.05, groups N and Vas com-
pared to group III). These results confirm our studies using 15-DS 
and Cy A after allogeneic cardiac transplantation in primates. In this 
study, 15-DS in combination with CyA was also able to reduce the 
number of acute rejection per animal significantly when compared 
to the other groups which were treated with either CyA or 15-DS 
alone. In the same model after renal transplantation, even long-term 
graft non-reactivity was achieved after initial treatment with 15-DS 
and CyA, as mentioned previously. 
The histopathology of the rejecton episodes also showed dif-
ferent results for the examined groups. In the control group, hype-
racute and mixed (hyperacute and acute cellular) rejection were 
mainly present (890/o). 
In the treated groups II, III and N, the acute cellular type of 
transplant reaction was predominant besides the mixed type. In 
these groups only one hyperacute rejection episode occurred in 
each group. 
In the 15-DS treated group V, no hyperacute rejection episode 
occurred, and 61.5% of all histology results were negative with re-
gard to acute rejection. Also in the 15-DS treated group N over70% 
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of the biopsy results were normal with no evidence of rejection 
features. 
Thus, 15-DS treatment led not only to a decreased number of 
acute rejection episodes, but also to a lowered incidence of severe 
hyperacute rejections. 
This is particularly important, because it has been shown in 
earlier studies after xenogeneic transplantation that the acute cellu-
lar type of rejection can be treated with additional anti-rejection 
therapy in contrast to vascular or hyperacute rejection episodes 
(89). 
As a new immunosuppressive agent, FK 506 has also been 
described to be effective after cardiac xenotransplantation in rats 
(122). FK 506 is thought to exert its effect by inhibiting IL 2 produc-
tion and IL 2 receptor expression on lymphocytes. One of the major 
problems of this drug, however, is its toxicity. Used as monotherapy 
and in combination with Cy A, there was a high incidence of toxic 
side effects after xenogenic skin transplantation in rodents (115). In 
combination with RATG, HSU et al. have described a synergism of 
both drugs after xenotransplantation with a lowered incidence of 
toxic side effects (119). FK 506 in combination with 15-DS also pro-
longed hamster-to-rat cardiac xenograft survival with reduced toxic 
side effects due to a lowered dosage being administered (123). 
The use of monoclonal antibodies has also been studied in the 
xenotransplant model. The combination of anti-CD4 and anti-CDS 
prolonged both allo- and xenogeneic skin grafts (124). Anti-CD4 
alone successfully prolonged xenografts only, while anti-CDS alone 
showed no effect after allo- and xenotransplantation. The combina-
tion of anti-CD4 with very low doses of CyA produced significant 
prolongation of both xeno- and allografts. This report confirms the 
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central role of CD4-positive cells in the reponse to xenogeneic tis-
sue. 
The results of cyto-immunological monitoring showed a signi-
ficant increase in the percentages of activated lymphocytes within 
the mononuclear concentrate of the peripheral blood during acute 
rejection episodes in all treatment groups. This also confirms earlier 
studies that cyto-immunological monitoring is a reliable method of 
detecting acute rejections after xenogeneic cardiac transplantation 
(89). 
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2.4.2. Clinical xenotransplantation 
Pioneering work has been performed by Reemtsma et al. in the 
field of xenogeneic kidney transplantation using chimpanzee do-
nors in human patients (125), followed by STARZL et al. using ba-
boons as donors (126). However, due to the relatively poor results 
compared with allogeneic transplantation, these projects were dis-
continued. In the field of cardiac transplantation, HARDY et al. re-
ported the first clinical xenogeneic heart transplantation, in which 
a chimpanzee heart was transplanted into a 68 year old man with 
cardiogenic shock (127). This was the first clinical heart transplan-
tation. The heart failed, 1 hour after implantation, probably as a 
result of gross weight mismatch between donor and recipient. Furt-
her clinical reports derive from COOLEY et al. who used a sheep 
heart (128) and from BARNARD (129). The latter used a chimpanzee 
heart in the heterotopic position in 1 patient, and a baboon heart in 
another, while awaiting a suitable human heart. Both patients, how-
ever, died within a short space of time due to severe hyperacute 
rejection. 
The most recent case reported by BAILEY and coworkers is 
also the most successful one (90). A neonate with hypoplastic left 
heart syndrome who received a baboon heart died after 20 postope-
rative days from multiorgan failure and ongoing haemolysis. The 
donor heart was ABO-incompatible and the phenomenon of on-
going haemolysis was probably caused by humoral anti-ABO anti-
bodies. Should this single clinical finding be representative of do-
nor/ recipient ABO-incompatibility, the role of the ABO-blood 
groups systems become especially significant. Due to the relative 
scarcity of 0-type non-human primates, as mentioned before, this 
would therefore exclude 0-type recipients from xenotransplanta-
tion. Although pretransplant splenectomy of the recipient may eli-
minate the deleterious effects of ABO-incompatibility (130), the ef-
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ficacy of this procedure in cardiac xenotransplantation is doubtful 
(131). 
Clinical preconditions for clinical xenotransplantation: 
Before clinical application, the following preconditions must be 
considered in accordance with BAILEY and coworkers (90): 
Pretransplant immunological tests should include at least 6 indivi-
dual animals: A mixed lymphocyte culture is neccessary in which 
the responsiveness of recipient lymphocytes to the cells of the po-
tential donor is examined in order to select the most suitable donor 
animal. In addition, the usual direct lymphocytotoxic crossmatch 
should also be performed. The presence of maternal antibodies 
must, however, be considered and excluded before final evalua-
tion. This testing, however, requires a lot of work done by technici-
ans in an immunological laboratory and can therefore only be done 
in a clinical situation. 
ABO-compatibility is essential and a conditio sine qua non. 
Since primates such as baboons or Vervet monkeys do rarely have 
the blood group 0, neonates and infants with blood group O cannot 
be considered for xenotransplantation. 
Postoperatively, every blood transfusion administered to the 
transplant recipient should be tested for lymphocytotoxic antibo-
dies against the donor animal and for CMV-seronegativity. Only 
irradiated packed cells, after 4 repeated washings should be used. 
Finally, non-human primates are known to harbour a substan-
tial population of virus species that could cause serious disease or 
death, especially in the immunosuppressed transplant recipient 
(132). Prior to their utilization as organ donors in the clinical setting, 
therefore, these animals must be screened for different virus species 
such as the Herpes simplex type, cytomegalovirus, the simian im-
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munodeficiency retrovirus and other human immunodeficiency vi-
rus species related to the retroviral strains (132). 
The most important precondition is the adequate suppression 
of the immune response to xenogeneic transplantation. Concordant 
xenografts would a pp ear to be more suitable for clinical application 
in the near future, because several immunosuppressive agents 
showed some potential in overcoming rejection between concor-
dant species. All reports are consistent with regard to the superiority 
of combination therapy when compared to monotherapy. 
As discussed before, the most effective immunosuppression 
presently available involves the combination of Cy A, azathioprine, 
methylprednisolone and either polyclonal or monoclonal antilym-
phocyte antibodies. The use of 15-DS showed promising results 
experimentally, particularly with regard to the incidence and num-
ber of acute rejection episodes. In view of the evidence implicating 
macrophage activity in the xenogeneic response, further studies of 
anti-macrophage agents, like 15-DS seem to be extremely impor-
tant. First clinical trials using 15-DS after allotransplantation must, 
however, be awaited, before using this new drug in clinical xeno-
transplantation. 
The use of non-human primates as concordant donors for hu-
mans poses several problems. The baboon does not grow to a size 
large enough to make it a suitable heart donor for adult humans, 
although their use might well be possible for paediatric transplan-
tation. Other higher primates, such as chimpanzees are very rare 
and are therefore not suitable for transplantation purposes. In addi-
tion, there are moral and ethical objections to the use of such ani-
mals 033). 
Thus, the ultimate goal in the field of xenotransplantation 
would be the use of discordant species as donors. Despite impor-
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tant advances in chemical, radiation and mechanical immunosup-
pression, significant problems are yet to be solved. The presence of 
preformed natural antibodies remains a formidable obstacle in dis-
cordant xenotransplantation. Combination therapy is necessary sa-
fely reducing antibody production and at the same time suppres-
sing cell-mediated immunity. For this aim, further work is necessary 
to characterize the naturally occurring xenoantibody as well as the 
antigens it recognizes. 
In the final analysis, transplant research in this field should aim 




Fig.1: Operative technique of heterotopic heart transplanta-
tion in the neck according to the technique of MANN ( CCA = com-
mon carotid artery, IJV = internal jugular vein, Ao= ascending aorta, 
PA = pulmonary artery). 
Fig.2: Operative situs after classical renal transplantation. The 
renal artery is anastomosed to the common iliac artery and the renal 
vein to the common iliac vein. The ureter is anastomosed to the 
bladder tunnelled under bladder muscle. 
Fig.3: A typical mononuclear concentrate of the peripheral 
blood during an acute inflammation process: 
a) normal lymphocyte, b) activated lymphocyte, identifiable by the 
noticeable increase in size, pronounced cytoplasmic basophilia and 
fluffy nuclear structure; c) lympho- or immunoblast, 2 - 3 times en-
larged, when compared to the normal lymphocyte; note the baso-
philia of the cytoplasm, nucleoli are clearly visible within the cell 
nucleus (Pappenheim staining, x1250). 
Fig.4: Mild acute rejection episode: perivascular and scanty 
interstitial mononuclear cell infiltrations, slight interstitial oedema, 
but no sign of myocyte damage. Figs. 4-9 and 19-22 were generous-
ly supplied by Professor Alan Rose. 
Fig.5: Moderate acute rejection: Diffuse interstitial mononu-
clear cell infiltration, more pronounced interstitial oedema and 
signs of myocyte necrosis. 
Fig.6: Severe acute rejection: In addition to the mononuclear 
cells, there is infiltration of neutrophile granulocytes, diffuse myo-
cyte necrosis and haemorrhage. 
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Fig.7: Mild renal rejection: Perivascular lymphocytic infiltrates 
and only scanty interstitial mononuclear cell infiltrations are visible. 
Fig.8: Moderate renal rejection: There is mononuclear cell in-
filtration with evidence of acute tubular necrosis. 
Fig.9: Severe renal rejection: Diffuse lymphocytic and neutro-
phile granulocyte cell infiltration with signs of haemorrhage and 
diffuse acute tubular necrosis are obvious. 
Fig.10: Survival rates for the different treatment groups after 
heart transplantation. Increased graft survival is already apparent 
with 15-DS treatment alone (group IB). The best graft survival was 
achieved in group ID (15-DS and Cy A), when compared to the con-
trol group IA. 
Fig.11: Survival rates after renal transplantation. Only group 
IID (15-DS and Cy A) showed a significant increase in survival time 
when compared to the control group IIA. 3 primates are still alive 
370, 286 and 274 days after surgery, 1 baboon died 194 days after 
transplantation. 
Fig.12: Experimental endpoints after heart transplantation. 
Most grafts stopped functioning due to acute graft rejection. One 
animal in group IB died from gastrointestinal complications proba-
bly due to 15-DS therapy. 
Fig.13: Experimental endpoints after renal allografting. Urae-
mia and hyperkalaemia as a result of acute graft rejection were the 
dominant causes of death in groups IIA and IIB. 2 animals in group 
IIB died from gastrointestinal complications. 3 out of 8 animals of 
group IID are still alive (COD?= unknown cause of death). 
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Fig.14: Cyto-immunological monitoring after cardiac trans-
plantation. In the treatment groups 1B and ID, a significant increase 
of activated lymphocytes within the mononuclear concentrate of 
the peripheral blood was noted during acute rejection (p < 0.05). 
Fig.15: Cyto-immunological monitoring after renal transplan-
tation. During acute rejection an increase of activated lymphocytes 
within the mononuclear concentrate of the peripheral blood was 
also noted. However, the increase of these activated cells proved 
not to be significant except for group UD (p < 0.05). 
Fig.16: Urea levels after renal transplantation. After an initial 
postoperative rise, the levels returned to acceptable levels again in 
groups UC and UD. 
Fig.17:Creatinine levels after renal allografting. In groups UC 
and UD, these levls dropped again after an initial postoperative rise. 
Fig.18: Creatinine levels before and during acute rejection af-
ter renal transplantation. Except in the combination treatment 
group UD, a rise of creatinine was noted during acute renal rejection 
episodes. 
Fig.19: Acute cellular rejection after cardiac xenotransplanta-
tion: A similar picture occurred after allotransplantation: Mononu-
clear cell infiltration occurs perivascularly and in the interstitium, in 
combination with myocyte necrosis and interstitial oedema. 
Fig.20: Hyperacute rejection after xenogeneic transplantation: 
interstitial haemorrhage and interstitial oedema is seen without any 
mononuclear cell infiltrate. 
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Fig.21: Macroscopic picture of hyperacute rejection; note the 
swelling of the heart and the haemorrhage on the surface. 
Fig.22: Mixed type of acute rejection after xenogeneic trans-
plantation. In addition to the features of hyperacute rejection de-
monstrated above, typical signs of cellular rejection such as mono-
nuclear cell infiltrations are seen as well. 
Fig.23: Xenograft survival rates for the different treatment 
groups. The best graft survival rate was achieved with a combina-
tion of CyA, azathioprine, methylprednisolone and RATG (group 
III). The termination of graft survival within the first 2 postoperative 
days always corresponded always to the occurrence ofhyperacute 
rejection. 
Fig.24: Causes of experiment termination shown graphically 
in a pie diagram. Rejection (hyperacute, cellular or mixed) was the 
dominant cause in groups I and II, while infections and gastrointe-
stinal complications occurred mainly in groups III and IV. In group 
V, less lethal treatment related side effects were seen. 
Fig.25: Histopathology of the myocardial biopsies. Most of the 
biopsy findings in groups I, II and III showed evidence of rejection; 
in groups IV and V, 72.7% and 61.5% of the results were normal with 
no sign of acute rejection. 
Fig.26: Results of the cyto-immunological monitoring after xe-
nogeneic transplantation. All acute rejection episodes in the treated 
groups II, III and IV were accompanied by a significant rise of acti-
vated lymphocytes within the mononuclear concentrate of the pe-
ripheral blood (AR= acute rejection episode). 
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Table 1: Immunosuppressive protocol after cardiac (group I) 
and renal (group II) transplantation. 
Table 2: List of experimental animals, date of transplantation, 
date of death, survival and cause of death after cardiac allotrans-
plantation. 
Table 3: Mean graft survival rate (GSR) in days after heteroto-
pic cardiac (group I) allotransplantation. 
Table 4: List of experimental animals, date of transplantation, 
date of death, survival and cause of death after renal allotransplan-
tation. 
Table 5: Mean graft survival rate (GSR) in days after renal 
(group II) allotransplantation. 
Table 6: Number of acute rejection episodes per animal and 
biopsy after cardiac (group I) transplantation. The number of rejec-
tion episodes per animal was calculated in relation to every biopsy 
because the animals had different survival periods. 
Table 7: Number of acute rejection episodes per animal and 
biopsy after renal (group II) transplantation. 
Table 8: Induction of graft nonreactivity after heart (group I) 
and kidney (group II) transplantation. 
Table 9: Immunosuppressive protocol in the different groups 
after heterotopic cardiac xenotransplantation. 
Table 10: List of experimental animals, date of transplantation, 
date of death, survival and cause of death after cardiac xenotrans-
plantation. 
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Table 11: Graft survival rate ( GSR) in days after cardiac xeno-
transplantation within the different groups. 
Table 12: Number of acute rejections in each treatment group. 
In group IV and in group V only 0.14 rejections per animal and 
biopsy were observed. These numbers differed significantly from 
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